Cover
Cover | 9 Months Ended |
Sep. 30, 2022 | |
Entity Addresses [Line Items] | |
Document Type | S-1 |
Amendment Flag | false |
Entity Registrant Name | ADHERA THERAPEUTICS, INC. |
Entity Central Index Key | 0000737207 |
Entity Tax Identification Number | 11-2658569 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | Adhera Therapeutics, Inc. |
Entity Address, Address Line Two | 8000 Innovation Parkway |
Entity Address, City or Town | Baton Rouge |
Entity Address, State or Province | LA |
Entity Address, Postal Zip Code | 70820 |
City Area Code | (919) |
Local Phone Number | 518-3748 |
Entity Filer Category | Non-accelerated Filer |
Entity Small Business | true |
Entity Emerging Growth Company | false |
Business Contact [Member] | |
Entity Addresses [Line Items] | |
Entity Address, Address Line One | Adhera Therapeutics, Inc. |
Entity Address, Address Line Two | 8000 Innovation Parkway |
Entity Address, City or Town | Baton Rouge |
Entity Address, State or Province | LA |
Entity Address, Postal Zip Code | 70820 |
City Area Code | 919 |
Local Phone Number | 518-3748 |
Contact Personnel Name | Zahed Subhan |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Current assets | |||
Cash | $ 133,000 | $ 76,000 | $ 1,000 |
Prepaid expenses | 123,000 | 120,000 | |
Total current assets | 256,000 | 196,000 | 1,000 |
Total assets | 256,000 | 196,000 | 1,000 |
Current liabilities | |||
Accounts payable | 2,312,000 | 2,309,000 | 2,257,000 |
Due to related parties | 5,000 | 46,000 | 4,000 |
Accrued expenses | 4,041,000 | 3,110,000 | 2,112,000 |
Accrued dividends | 453,000 | 5,477,000 | 4,083,000 |
Term loans | 6,870,000 | 5,677,000 | 5,677,000 |
Convertible notes payable, net | 1,122,000 | 986,000 | 641,000 |
Derivative liabilities | 7,260,000 | 7,697,000 | |
Total current liabilities | 22,063,000 | 25,302,000 | 14,774,000 |
Total liabilities | 22,063,000 | 25,302,000 | 14,774,000 |
Commitments and contingencies (Note 9) | |||
Stockholders’ deficit | |||
Preferred stock, value | |||
Common stock value | 18,000 | 5,000 | 3,000 |
Additional paid-in capital | 33,547,000 | 27,906,000 | 29,836,000 |
Accumulated deficit | (55,370,000) | (53,017,000) | (44,612,000) |
Treasury stock (5,954 shares) | (2,000) | ||
Total stockholders’ deficit | (21,807,000) | (25,106,000) | (14,773,000) |
Total liabilities and stockholders’ deficit | 256,000 | 196,000 | 1,000 |
Series C Convertiable Preferred Stock [Member] | |||
Stockholders’ deficit | |||
Preferred stock, value | |||
Series D Convertiable Preferred Stock [Member] | |||
Stockholders’ deficit | |||
Preferred stock, value | |||
Series E Convertiable Preferred Stock [Member] | |||
Stockholders’ deficit | |||
Preferred stock, value | |||
Series F Convertiable Preferred Stock [Member] | |||
Stockholders’ deficit | |||
Preferred stock, value | |||
Series G Convertiable Preferred Stock [Member] | |||
Stockholders’ deficit | |||
Preferred stock, value |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Preferred stock, par value | $ 0.01 | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 100,000 | 100,000 | 100,000 |
Common stock, par value | $ 0.006 | $ 0.006 | $ 0.006 |
Common stock, shares authorized | 180,000,000 | 180,000,000 | 180,000,000 |
Common stock, shares issued | 3,160,877 | 853,946 | 560,140 |
Common stock, shares outstanding | 3,160,877 | 853,946 | 560,140 |
Treasury stock, shares | 5,954 | 5,954 | |
Series C Convertible Preferred Stock [Member] | |||
Preferred stock, par value | $ 0.01 | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 1,200 | 1,200 | 1,200 |
Preferred stock, shares issued | 100 | 100 | 100 |
Preferred stock, shares outstanding | 100 | 100 | 100 |
Preferred stock, liquidation preference value | $ 510,000 | $ 510,000 | $ 510,000 |
Series D Convertible Preferred Stock [Member] | |||
Preferred stock, par value | $ 0.01 | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 220 | 220 | 220 |
Preferred stock, shares issued | 40 | 40 | 40 |
Preferred stock, shares outstanding | 40 | 40 | 40 |
Preferred stock, liquidation preference value | $ 12,000 | $ 12,000 | $ 12,000 |
Series E Convertible Preferred Stock [Member] | |||
Preferred stock, par value | $ 0.01 | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 3,500 | 3,500 | 3,500 |
Preferred stock, shares issued | 267 | 3,326 | 3,458 |
Preferred stock, shares outstanding | 267 | 3,326 | 3,458 |
Preferred stock, liquidation preference value | $ 1,788,319 | $ 21,618,999 | $ 21,618,999 |
Series F Convertible Preferred Stock [Member] | |||
Preferred stock, par value | $ 0.01 | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 2,200 | 2,200 | 2,200 |
Preferred stock, shares issued | 0 | 358 | 361 |
Preferred stock, shares outstanding | 0 | 358 | 361 |
Preferred stock, liquidation preference value | $ 2,277,509 | $ 2,277,509 | |
Series G Convertible Preferred Stock [Member] | |||
Preferred stock, par value | $ 0.01 | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 6,000 | 6,000 | 6,000 |
Preferred stock, shares issued | 0 | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 | 0 |
Preferred stock, liquidation preference value | $ 5,000 | $ 5,000 | $ 5,000 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Operating expenses | ||||||
Sales and marketing | $ 17 | $ 17 | $ 839 | |||
General and administrative | 548 | 232 | 1,257 | 454 | 657 | 1,198 |
Total operating expenses | 548 | 232 | 1,257 | 471 | 674 | 2,037 |
Loss from operations | (548) | (232) | (1,257) | (471) | (674) | (2,037) |
Other income (expense) | ||||||
Interest expense | (317) | (261) | (989) | (749) | (1,035) | (935) |
Other income | 45 | |||||
Initial and change in the fair value of derivative liabilities | (254) | (2,968) | 1,425 | (3,055) | (4,103) | |
Gain (loss) on extinguishment of debt | 92 | (177) | 307 | (177) | (141) | |
Amortization of debt discount | (777) | (101) | (1,265) | (230) | (398) | (839) |
Total other expense, net | (1,256) | (3,507) | (522) | (4,211) | (5,677) | (1,729) |
Loss before provision for income taxes | (6,351) | (3,766) | ||||
Provision for income taxes | ||||||
Net loss | (1,804) | (3,739) | (1,779) | (4,682) | (6,351) | (3,766) |
Accrued and deemed dividends | (8) | (406) | (574) | (1,679) | (2,054) | (1,540) |
Net Loss Applicable to Common Stockholders | $ (1,812) | $ (4,145) | $ (2,353) | $ (6,361) | $ (8,405) | $ (5,306) |
Net loss per share – Common Stockholders - basic and diluted | $ (0.57) | $ (6.38) | $ (1.16) | $ (10.83) | $ (12.84) | $ (9.67) |
Weighted average shares outstanding - basic and diluted | 3,160,877 | 649,321 | 2,019,953 | 587,117 | 654,700 | 548,514 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands | Preferred Stock [Member] Series C Preferred Stock [Member] | Preferred Stock [Member] Series D Preferred Stock [Member] | Preferred Stock [Member] Series E Preferred Stock [Member] | Preferred Stock [Member] Series F Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total | Treasury Stock [Member] |
Beginning balance, value at Dec. 31, 2019 | $ 3 | $ 29,439 | $ (39,327) | $ (9,887) | |||||
Beginning balance, shares at Dec. 31, 2019 | 100 | 40 | 3,478 | 361 | 547,981 | ||||
Accrued dividend | (1,540) | (1,540) | |||||||
Issuance of warrants and common stock with convertible notes | 294 | 294 | |||||||
Issuance of warrants and common stock with convertible notes, shares | |||||||||
Issuance of common stock for Series E conversion | 21 | 23 | |||||||
Issuance of common stock for Series E conversion, shares | (20) | 12,159 | |||||||
Share based compensation | 8 | 8 | |||||||
Beneficial conversion feature convertible notes | 95 | 95 | |||||||
Net loss | (3,766) | (3,766) | |||||||
Ending balance, shares at Dec. 31, 2020 | 100 | 40 | 3,458 | 361 | 560,140 | ||||
Ending balance, value at Dec. 31, 2020 | $ 3 | 29,836 | (44,612) | (14,773) | |||||
Accrued dividend | 505 | (882) | (377) | ||||||
Beneficial conversion feature convertible notes | 19 | 19 | |||||||
Net loss | (428) | (428) | |||||||
Issuance of common stock with term loan | 26 | 26 | |||||||
Issuance of common stock with term loan, shares | 25,900 | ||||||||
Issuance of warrants with convertible notes | 28 | 28 | |||||||
Ending balance, shares at Mar. 31, 2021 | 100 | 40 | 3,458 | 361 | 586,040 | ||||
Ending balance, value at Mar. 31, 2021 | $ 3 | 30,414 | (45,922) | (15,505) | |||||
Beginning balance, value at Dec. 31, 2020 | $ 3 | 29,836 | (44,612) | (14,773) | |||||
Beginning balance, shares at Dec. 31, 2020 | 100 | 40 | 3,458 | 361 | 560,140 | ||||
Net loss | (4,682) | ||||||||
Conversion of Series E Preferred to common stock | 4 | ||||||||
Ending balance, shares at Sep. 30, 2021 | 100 | 40 | 3,400 | 361 | 728,778 | ||||
Ending balance, value at Sep. 30, 2021 | $ 4 | 30,749 | (50,973) | (20,239) | |||||
Beginning balance, value at Dec. 31, 2020 | $ 3 | 29,836 | (44,612) | (14,773) | |||||
Beginning balance, shares at Dec. 31, 2020 | 100 | 40 | 3,458 | 361 | 560,140 | ||||
Issuance of warrants and common stock with convertible notes | 320 | 320 | |||||||
Issuance of warrants and common stock with convertible notes, shares | 35,767 | ||||||||
Issuance of common stock for Series E conversion | $ 1 | 115 | 116 | ||||||
Issuance of common stock for Series E conversion, shares | (132) | 77,551 | |||||||
Net loss | (6,351) | (6,351) | |||||||
Accrued and deemed dividend | 541 | (2,054) | (1,513) | ||||||
Reclassification of derivative from equity | (3,462) | (3,462) | |||||||
Issuance of common stock for cashless exercise of warrants | |||||||||
Issuance of common stock for cashless exercise of warrants, shares | 10,341 | ||||||||
Issuance of common stock with term loan | $ 1 | 553 | 554 | ||||||
Issuance of common stock with term loan, shares | 168,294 | ||||||||
Issuance of common stock for Series F conversion | 3 | 3 | |||||||
Issuance of common stock for Series F conversion, shares | (3) | 1,853 | |||||||
Ending balance, shares at Dec. 31, 2021 | 100 | 40 | 3,326 | 358 | 853,946 | ||||
Ending balance, value at Dec. 31, 2021 | $ 5 | 27,906 | (53,017) | (25,106) | |||||
Beginning balance, value at Mar. 31, 2021 | $ 3 | 30,414 | (45,922) | (15,505) | |||||
Beginning balance, shares at Mar. 31, 2021 | 100 | 40 | 3,458 | 361 | 586,040 | ||||
Issuance of common stock for Series E conversion | 10 | 10 | |||||||
Issuance of common stock for Series E conversion, shares | (8) | 5,051 | |||||||
Net loss | (514) | (514) | |||||||
Issuance of common stock for cashless exercise of warrants | |||||||||
Issuance of common stock for cashless exercise of warrants, shares | 2,679 | ||||||||
Issuance of warrants with convertible notes | 69 | 69 | |||||||
Accrued and deemed dividend | 11 | (392) | (381) | ||||||
Accrued and deemed dividend | (11) | 392 | 381 | ||||||
Ending balance, shares at Jun. 30, 2021 | 100 | 40 | 3,450 | 361 | 593,770 | ||||
Ending balance, value at Jun. 30, 2021 | $ 3 | 30,504 | (46,828) | (16,340) | |||||
Issuance of common stock for Series E conversion, shares | (50) | ||||||||
Net loss | (3,739) | (3,739) | |||||||
Reclassification of derivative from equity | 21 | 21 | |||||||
Issuance of common stock with term loan | $ 1 | 84 | 85 | ||||||
Issuance of common stock with term loan, shares | 85,000 | ||||||||
Accrued and deemed dividend | (25) | 406 | (381) | ||||||
Accrued and deemed dividend | 25 | (406) | 381 | ||||||
Issuance of common stock with convertible notes | 157 | 157 | |||||||
Issuance of common stock with convertible notes, shares | 25,008 | ||||||||
Conversion of Series E Preferred to common stock | |||||||||
Conversion of Series E Preferred to common stock, shares | 25,000 | ||||||||
Ending balance, shares at Sep. 30, 2021 | 100 | 40 | 3,400 | 361 | 728,778 | ||||
Ending balance, value at Sep. 30, 2021 | $ 4 | 30,749 | (50,973) | (20,239) | |||||
Beginning balance, value at Dec. 31, 2021 | $ 5 | 27,906 | (53,017) | (25,106) | |||||
Beginning balance, shares at Dec. 31, 2021 | 100 | 40 | 3,326 | 358 | 853,946 | ||||
Accrued dividend | (364) | (364) | |||||||
Net loss | (74) | (74) | |||||||
Issuance of common stock with term loan | 28 | 28 | |||||||
Issuance of common stock with term loan, shares | 12,721 | ||||||||
Issuance of common stock with convertible notes | 18 | 18 | |||||||
Issuance of common stock with convertible notes, shares | 12,500 | ||||||||
Ending balance, shares at Mar. 31, 2022 | 100 | 40 | 3,326 | 358 | 879,167 | ||||
Ending balance, value at Mar. 31, 2022 | $ 5 | 27,952 | (53,455) | (25,498) | |||||
Beginning balance, value at Dec. 31, 2021 | $ 5 | 27,906 | (53,017) | (25,106) | |||||
Beginning balance, shares at Dec. 31, 2021 | 100 | 40 | 3,326 | 358 | 853,946 | ||||
Net loss | $ (1,779) | ||||||||
Issuance of common stock with term loan, shares | 133,284 | ||||||||
Conversion of Series E Preferred to common stock | $ 5,056 | ||||||||
Ending balance, shares at Sep. 30, 2022 | 100 | 40 | 267 | 3,160,877 | |||||
Ending balance, value at Sep. 30, 2022 | $ 18 | 33,547 | (55,370) | (21,807) | (2) | ||||
Beginning balance, value at Mar. 31, 2022 | $ 5 | 27,952 | (53,455) | (25,498) | |||||
Beginning balance, shares at Mar. 31, 2022 | 100 | 40 | 3,326 | 358 | 879,167 | ||||
Accrued dividend | (202) | (202) | |||||||
Net loss | 99 | 99 | |||||||
Issuance of common stock with term loan | 11 | 11 | |||||||
Issuance of common stock with term loan, shares | 19,231 | ||||||||
Conversion of Series E Preferred to common stock | $ 12 | 5,044 | 5,056 | ||||||
Conversion of Series E Preferred to common stock, shares | (3,059) | 2,035,306 | |||||||
Conversion of Series F Preferred to common stock | $ 1 | 540 | 541 | ||||||
Conversion of Series F Preferred to common stock, shares | (358) | 233,127 | |||||||
Repurchase of common stock | (2) | (2) | |||||||
Repurchase of common stock, shares | (5,954) | ||||||||
Ending balance, shares at Jun. 30, 2022 | 100 | 40 | 267 | 3,160,877 | |||||
Ending balance, value at Jun. 30, 2022 | $ 18 | 33,547 | (53,558) | (19,995) | (2) | ||||
Accrued dividend | (8) | (8) | |||||||
Net loss | (1,804) | (1,804) | |||||||
Ending balance, shares at Sep. 30, 2022 | 100 | 40 | 267 | 3,160,877 | |||||
Ending balance, value at Sep. 30, 2022 | $ 18 | $ 33,547 | $ (55,370) | $ (21,807) | $ (2) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Cash Flows Used in Operating Activities: | ||||||
Net loss | $ (1,804,000) | $ (3,739,000) | $ (1,779,000) | $ (4,682,000) | $ (6,351,000) | $ (3,766,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Share based compensation | 0 | 0 | 0 | 0 | 8,000 | |
Amortization of debt discount and fees | 1,265,000 | 230,000 | 398,000 | 839,000 | ||
Accrued interest expense | 317,000 | 261,000 | 989,000 | 749,000 | 1,035,000 | 935,000 |
Derivative income (expense) | (1,425,000) | 3,055,000 | 4,103,000 | |||
(Gain) Loss on debt extinguishment | (92,000) | 177,000 | (307,000) | 177,000 | 141,000 | |
Changes in operating assets and liabilities: | ||||||
Prepaid expenses | (3,000) | (120,000) | 370,000 | |||
Accounts payable | (38,000) | 30,000 | 94,000 | 854,000 | ||
Accrued expenses | 36,000 | 72,000 | 36,000 | 172,000 | ||
Net Cash Used in Operating Activities | (1,262,000) | (369,000) | (664,000) | (588,000) | ||
Cash Flows Provided by Financing Activities: | ||||||
Proceeds from notes payable and convertible notes, net of original issue discounts | 2,200,000 | 591,000 | 840,000 | 653,000 | ||
Notes payable and convertible notes issuance costs | (328,000) | (72,000) | (101,000) | (114,000) | ||
Repurchase of common stock | (2,000) | |||||
Repayment of principal and interest on notes payable | (551,000) | |||||
Net Cash Provided by Financing Activities | 1,319,000 | 519,000 | 739,000 | 539,000 | ||
Net increase in cash | 57,000 | 150,000 | 75,000 | (49,000) | ||
Cash – Beginning of Period | 76,000 | 1,000 | 1,000 | 50,000 | ||
Cash - End of Period | $ 133,000 | 1,514,000 | 133,000 | 1,514,000 | 76,000 | 1,000 |
Supplementary Cash Flow Information: | ||||||
Cash paid for interest | 94,000 | |||||
Cash paid for taxes | ||||||
Non-cash Investing and Financing Activities: | ||||||
Issuance of common stock for conversion of Series E Preferred | 116,000 | 23,000 | ||||
Issuance of common stock for conversion of Series F Preferred | 3,000 | |||||
Debt discounts for issuance costs, warrants and derivatives | 10,000 | 320,000 | 294,000 | |||
Issuance of common stock for conversion of convertible notes | 28,000 | 111,000 | 554,000 | |||
Reclassification of derivative liability | 3,462,000 | |||||
Accrued and deemed dividends | 574,000 | 1,679,000 | 2,054,000 | 1,540,000 | ||
Beneficial conversion feature | $ 95,000 | |||||
Conversion of Series E Preferred stock to common stock | 5,056,000 | 4,000 | ||||
Conversion of Series F Preferred stock to common stock | 541,000 | |||||
Issuance of common stock and warrants with convertible notes | 20,000 | 473,000 | ||||
Cashless exercise of warrants | $ 4,000 |
Organization and Business Opera
Organization and Business Operations | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Organization and Business Operations | Note 1 – Organization and Business Operations Adhera Therapeutics, Inc. and its wholly-owned subsidiaries, MDRNA Research, Inc. (“MDRNA”), Cequent Pharmaceuticals, Inc. (“Cequent”), Atossa Healthcare, Inc. (“Atossa”), and IThenaPharma, Inc. (“IThena”) (collectively “Adhera,” or the “Company”), is an emerging specialty biotech company that, to the extent that resources and opportunities become available, is focused on drug development and commercialization of “small molecule” drugs to treat Parkinson’s disease (PD) and Type 1 diabetes. On July 28, 2021, we as licensee and Melior Pharmaceuticals II, LLC (“Melior II”) entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic and is, to the best of our knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, we were granted an exclusive license to use the Melior II Patents and know-how to develop products in consideration for cash payments upon meeting certain performance milestones as well as a royalty of 5% of gross sales. On August 20, 2021, we as licensee entered into an exclusive license agreement with Melior Pharmaceuticals I, Inc. (“Melior I”) for the development, commercialization and exclusive license of MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes. On October 20, 2021, we as licensee expanded the exclusive licensing agreement with Melior I to include two additional clinical indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation. To the extent that resources have been available, the Company has continued to work with its advisors in an effort to restructure our company and to identify additional strategic transactions to enhance the value of our company as such opportunities arise, including potential transactions and capital raising initiatives, as well as business combination transactions with operating companies. There can be no assurance that the Company will be successful at identifying any such transactions, that it will continue to have sufficient resources to actively attempt to identify such transactions, or that such transactions will be available upon terms acceptable to us or at all. If the Company does not complete any significant strategic transactions, or raise substantial additional capital, in the near future, it is likely that the Company will discontinue all operations and seek bankruptcy protection. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) | Note 1 – Organization and Business Operations Adhera Therapeutics, Inc. and its wholly-owned subsidiaries, MDRNA Research, Inc. (“MDRNA”), Cequent Pharmaceuticals, Inc. (“Cequent”), Atossa Healthcare, Inc. (“Atossa”), and IThenaPharma, Inc. (“IThena”) (collectively “Adhera,” or the “Company”), is an emerging specialty biotech company that, to the extent that resources and opportunities become available, is strategically evaluating its focus including a return to a drug discovery and development company. On July 28, 2021, we as licensee and Melior Pharmaceuticals II, LLC entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of our knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, we were granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments upon meeting certain performance milestones as well as a royalty of 5% of gross sales. On August 20, 2021, we as licensee entered into an exclusive license agreement with Melior Pharmaceuticals I, Inc. for the development, commercialization and exclusive license of MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes. On October 20, 2021, we as licensee expanded the exclusive licensing agreement with Melior Pharmaceuticals I, Inc. to include two additional clinical indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation. To the extent that resources have been available, the Company has continued to work with its advisors in an effort to restructure our company and to identify potential strategic transactions to enhance the value of our company as such opportunities arise, including potential transactions and capital raising initiatives involving the assets relating to our legacy RNA interference programs, as well as business combination transactions with operating companies. There can be no assurance that the Company will be successful at identifying any such transactions, that it will continue to have sufficient resources to actively attempt to identify such transactions, or that such transactions will be available upon terms acceptable to us or at all. If the Company does not complete any significant strategic transactions, or raise substantial additional capital, in the immediate future, it is likely that the Company will discontinue all operations and seek bankruptcy protection. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Accounting Policies [Abstract] | ||
Summary of Significant Accounting Policies | Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The information furnished in this Report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the nine months ended September 30, 2022, are not necessarily indicative of the results for the year ending December 31, 2022, or for any future period. Principles of Consolidation The consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive. Going Concern and Management’s Liquidity Plans The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2022, the Company had cash and cash equivalents of approximately $ 133,000 21.8 The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company recognized a net loss of approximately $ 1.8 1.3 55.4 In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for its our operations at terms acceptable to the Company or at all. General market conditions, as well as market conditions for companies in the Company’s financial and business position, as well as the ongoing issues arising from the COVID-19 pandemic, the Ukraine war and inflation and the Federal Reserve interest rate increases in response, and any recessionary environment or market downturns that could result, may make it difficult for the Company to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of its stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties. Reverse Stock-split On September 30, 2022, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the Delaware Secretary of State to effect a reverse stock split of all outstanding shares of the Company’s common stock at a ratio of 1-for-20. On October 5, 2022, the Company effected the 1-for-20 reverse stock split of its common stock. The reverse stock split did not cause an adjustment to the par value or the authorized shares of the common stock. As a result of the reverse stock split, the Company retroactively adjusted all outstanding common stock equivalents including options, warrants, convertible notes and other agreements with third parties. All disclosures of common shares and per common share data in the accompanying consolidated financial statements and related notes reflect the reverse stock split for all periods presented. As a result of the reverse split the Company recorded a $361,000 adjustment to the par value of common stock which was offset to additional paid-in capital. Summary of Significant Accounting Policies Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of six months or less at the time of purchase to be cash equivalents. As of December 31, 2021 and September 30, 2022, the Company had approximately $ 76,000 133,000 The Company deposits its cash with major financial institutions that may at times exceed the federally insured limit. As of December 31, 2021 and September 30, 2022, the Company did no 250,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances. Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of September 30, 2022, the Company measured conversion features on outstanding convertible notes and warrants as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 7.3 million. The value of the derivative liability as of September 30, 2022, was determined by using the binomial lattice model using the following inputs: risk free rate of 4.05% to 4.25% , volatility of 147% to 317% and time to maturity of zero to one year no liabilities or assets measured at fair value on a non-recurring basis as of September 30, 2022. Schedule of Fair Value Measurements Fair Value Measurements at September 30, 2022 Quoted Other Significant (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liabilities $ - $ - $ 7,260 $ 7,260 Total $ - $ - $ 7,260 $ 7,260 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments (in thousands) Warrants Notes Total Nine-Months Ended September 30, 2022 (in thousands) Warrants Notes Total Balance at December 31, 2021 $ 5,336 $ 2,361 $ 7,697 Initial valuation of derivative liabilities included in debt discount 1,151 163 1,314 Initial valuation of derivative liabilities included in derivative expense — 108 108 Reclassification of derivative liabilities loss to gain on debt extinguishment — (325 ) (325 ) Change in fair value included in derivative expense (318 ) (1,216 ) (1,534 ) Balance at September 30, 2022 $ 6,169 $ 1,091 $ 7,260 ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments. Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”), the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assesses whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet those requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position. Convertible debt – beneficial conversion feature Prior to the Company’s adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options Derivatives and Hedging—Contracts in Entity’s Own Equity Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) If the conversion feature does not qualify for derivative treatment, the convertible debt is treated as traditional debt. Recently Issued Accounting Pronouncements Recently Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements. In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic: 1. An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. 2. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: a. For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider: i. An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) ii. An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50. b. For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. 3. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows: a. A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs. b. A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest. c. Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year. The adoption by the Company as of January 1, 2022, did not have a significant impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures. Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options, convertible notes and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) The following table presents the computation of net loss per share (in thousands), except share and per share data): Schedule of Earnings Per Share, Basic and Diluted 2022 2021 2022 2021 Three Months Ended Nine Months Ended 2022 2021 2022 2021 Numerator Net loss $ (1,804 ) $ (3,739 ) $ (1,779 ) $ (4,682 ) Dividends (8 ) (406 ) (574 ) (1,679 ) Net Loss allocable to common stockholders $ (1,812 ) $ (4,145 ) $ (2,353 ) $ (6,361 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 3,160,877 649,321 2,019,953 587,117 Net loss per share of common stock, basic and diluted Net loss per share $ (0.57 ) $ (6.38 ) $ (1.16 ) $ (10.83 ) The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 Nine-Months Ended September 30, 2022 2021 Stock options outstanding 19,000 19,378 Convertible notes 2,389,770 1,216,640 Warrants 5,192,652 3,065,318 Series C Preferred Stock 3,334 3,334 Series D Preferred Stock 2,500 2,500 Series E Preferred Stock 178,833 2,175,826 Series F Preferred Stock — 225,995 Total 7,786,089 6,708,991 Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised if and when a forfeiture becomes probable. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. | Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of Company’s management, who is responsible for their integrity and objectivity. Principles of Consolidation The consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive. Going Concern and Management’s Liquidity Plans The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2021, the Company had cash and cash equivalents of approximately $ 76,000 25.1 The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net loss of approximately $ 6.4 million for the year ended December 31, 2021 and used cash in operating activities of approximately $ 664,000 . The Company had an accumulated deficit of approximately $ 53.0 million as of December 31, 2021. In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for its our operations at terms acceptable to the Company or at all. General market conditions, as well as market conditions for companies in the Company’s financial and business position, as well as the ongoing issue arising from the COVID-19 pandemic, may make it difficult for the Company to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of its stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties. Summary of Significant Accounting Policies Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. As of December 31, 2021, the Company had approximately $ 76,000 in cash equivalents. The Company deposits its cash with major financial institutions and may at times exceed the federally insured limit. At December 31, 2021, the Company’s cash balance did not exceed the federal insurance limit. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances. Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of December 31, 2021, the Company measured conversion features on outstanding convertible notes and warrants as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 7.7 million. The value of the derivative liability as of December 31, 2021, was determined by using the binomial lattice model using the following inputs: 0.069 % to 1.26 % risk free rate, volatility of 255 % to 399 % and time to maturity of 0 - 0.60 years. There were no liabilities or assets measured at fair value on a non-recurring basis as of December 31, 2021, and there were no liabilities or assets measured at fair value on a recurring or non-recurring basis as of December 31, 2020. Schedule of Fair Value Measurements (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurements at December 31, 2021 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 7,697 $ 7,697 Total $ - $ - $ 7,697 $ 7,697 A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments Year Ended December 31, 2021 (In thousands) Warrants Notes Total Balance at December 31, 2020 $ — $ — $ — Initial valuation of derivative liabilities included in debt discount — 377 377 Initial valuation of derivative liabilities included in derivative expense 246 1,348 1,594 Reclassification of derivative liabilities gain to loss on debt extinguishment (52 ) (193 ) (245 ) Reclass from additional paid-in capital 3,107 355 3,462 Change in fair value included in derivative expense 2,035 474 2,509 Balance at December 31, 2021 $ 5,336 $ 2,361 $ 7,697 ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments. Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”), the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assesses whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet those requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position. Convertible debt – beneficial conversion feature Prior to the Company’s adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options Derivatives and Hedging—Contracts in Entity’s Own Equity Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible debt is treated as traditional debt. Recently Issued Accounting Pronouncements Recently Adopted In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements. Not Yet Adopted In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic: 1. An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. 2. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: a. For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider: i. An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments. ii. An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50. b. For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. 3. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows: a. A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs. b. A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest. c. Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures. Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options, convertible notes and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted (in thousands except share and per share data) 2021 2020 December 31, (in thousands except share and per share data) 2021 2020 Numerator Net loss $ (6,351 ) $ (3,766 ) Preferred stock dividends (2,054 ) (1,540 ) Net Loss allocable to common stockholders $ (8,405 ) $ (5,306 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 654,700 548,514 Net loss per share of common stock, basic and diluted Net loss per share, basic and diluted $ (12.84 ) $ (9.67 ) The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 Year Ended December 31, 2021 2020 Stock options outstanding 19,203 19,568 Convertible notes 2,434,842 1,682,930 Warrants 3,731,263 3,909,100 Series C Preferred Stock 3,334 3,334 Series D Preferred Stock 2,500 2,500 Series E Preferred Stock 2,162,076 2,102,801 Series F Preferred Stock 227,761 215,199 Total 8,580,979 7,935,432 As of December 31, 2021, the Company’s fully diluted common stock equivalents exceeded the 180,000,000 shares currently authorized prior to the reverse stock split. (See Note 11) Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised if and when a forfeiture becomes probable. Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. |
Prepaid Expenses
Prepaid Expenses | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Prepaid Expenses | ||
Prepaid Expenses | Note 3 – Prepaid Expenses As of September 30, 2022, and December 31, 2021, prepaid expenses were approximately $ 123,000 120,000 | Note 3 – Prepaid Expenses As of December 31, 2021, prepaid expenses totaled approximately $ 120,000 no |
Notes Payable and Convertible P
Notes Payable and Convertible Promissory Notes | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Debt Disclosure [Abstract] | ||
Notes Payable and Convertible Promissory Notes | Note 4 – Notes Payable and Convertible Promissory Notes The following table summarizes the Company’s outstanding term loans: Schedule of Outstanding Term Loans (in thousands) September 30, December 30, 2019 Term Loan $ 5,677 $ 5,677 2022 Term Loan 2,222 - Notes payable 7,899 5,677 Unamortized discounts (1,029 ) - Loans payable $ 6,870 $ 5,677 2019 Term Loans During 2019, the Company entered into term loan subscription agreements with certain accredited investors, pursuant to which the Company issued secured promissory notes in the aggregate principal amount of approximately $ 5.7 707,000 The promissory notes accrued interest at a rate of 12% 15% The unpaid principal balance of the notes, plus accrued and unpaid interest thereon, matured on June 28, 2020 On June 26, 2021, the holders of the 2019 Term Loans agreed to subordinate their lien and security interest in the assets of the Company and its subsidiaries as set forth in the Security Agreement dated June 28, 2019, to the holders of the June 2021 convertible notes. On April 19, 2022, a majority of the noteholders of the secured non-convertible promissory notes of the Company issued between June 18, 2019, and August 5, 2019, which matured on August 5, 2020, consented to forbear collection efforts until September 30, 2022. Accordingly, the collateral agent for the note holders in consideration of the signed noteholder agreements agreed to forbear all notes outstanding. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) The Company recognized approximately $ 212,000 637,000 215,000 637,000 As of September 30, 2022, the Company had approximately $ 2.7 5.7 2.7 2022 Term Loan On May 11, 2022, the Company entered into a Securities Purchase Agreement with investors whereby the Company issued the Purchasers Original Issue Discount Promissory Notes in the aggregate principal amount of $ 2,222,222 222,222 2,000,000 1,111,112 19,231 1,692,200 307,800 The Notes are due on the earliest to occur of (i) the 12-month anniversary of the original issuance date of the Notes, or May 11, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest. The Warrants are exercisable for a 66 November 11, 2027 0.80 The Company recorded a total debt discount of $ 1,693,000 222,222 307,800 11,820 1,151,000 The Company’s obligations under the Notes are secured by a first priority lien on all of the assets of the Company and its wholly-owned subsidiaries pursuant to a Security Agreement, dated May 11, 2022 and among the Company, its wholly-owned subsidiaries, the Purchasers, and the lead investor as the collateral agent. For the three and nine months ended September 30, 2022, the Company recognized approximately $ 562,300 663,300 45,400 70,600 No As of September 30, 2022, the Company has recorded $ 2,222,222 70,600 1,029,000 Convertible Promissory Notes The following table summarizes the Company’s outstanding convertible notes as of September 30, 2022, and December 31, 2021: Schedule of Convertible Promissory Notes (in thousands) September 30, 2022 December 31, 2021 Convertible Notes $ 1,300 $ 1,516 Unamortized discounts and fees (178 ) (530 ) Convertible notes payable, net $ 1,122 $ 986 Ten convertible notes with outstanding principal of approximately $ 1.1 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) Secured Convertible Promissory Note – February 2020 On February 5, 2020, the Company entered into a Securities Purchase Agreement with accredited investors and issued the investors, (i) original issue discount Convertible Promissory Notes with a principal of $ 550,500 10% 499,950 The Convertible Notes matured on August 5, 2020 10% 18% Until the Convertible Notes are no longer outstanding, the Convertible Notes are convertible, in whole or in part, at any time, and from time to time, into shares of Common Stock at the option of the noteholder. The conversion price is the lower of: (i) $ 10.00 70% 60% 1.00 The exercise price of the Warrants shall be equal to the conversion price of the Convertible Notes, provided, that on the date that the Convertible Notes are no longer outstanding, the exercise price shall be fixed at the conversion price of the Convertible Notes on such date, with the exercise price of the Warrants thereafter (and the number of shares of Common Stock issuable upon the exercise thereof) being subject to adjustment as set forth in the Warrants. The warrants have a 5 The Company recorded a discount related to the Warrants of approximately $ 322,000 30,000 53,000 21,000 38,000 381,000 On March 19, 2021, the holder of the Convertible Note converted $ 25,900 25,900 On July 29, 2021, the holder of the Convertible Note converted $ 27,500 27,500 On August 16, 2021, the holder of the Convertible Note converted $ 25,000 25,000 On September 13, 2021, the holder of the Convertible Note converted $ 32,500 32,500 On October 4, 2021, the holder of the Convertible Note converted $ 26,250 26,250 On November 29, 2021, the holder of the Convertible Note converted $ 31,150 31,151 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) The total note principal and interest converted during the year ended December 31, 2021, was $ 168,300 168,294 554,000 386,000 245,000 245,000 141,000 On January 27, 2022, the conversion price of the notes and warrants was adjusted to be the lower of (x) 60% 0.78 For the three and nine months ended September 30, 2022, the Company recognized approximately $ 21,000 66,800 25,000 76,000 As of September 30, 2022, the Company had accrued interest on the February 2020 Convertible Note of approximately $ 168,000 As of September 30, 2022, the Company remains in default on the repayment of remaining principal of $ 457,359 140 The 40% premium will be recorded once a demand occurs Secured Convertible Promissory Note – June 2020 On June 26, 2020, the Company issued to an existing investor in the Company a 10% 58,055 52,500 5,555 December 26, 2020 10% 14,000 18% The Note is convertible, in whole or in part, into shares of common stock of the Company at the option of the noteholder at a conversion price of $ 0.40 (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be 65% of the lowest closing bid price of the Company’s common stock as reported on its principal trading market for the twenty consecutive trading day period ending on (and including) the trading day immediately preceding the date on which the conversion notice was delivered. The conversion price shall also be adjusted for subsequent equity sales by the Company. Because the share price on the commitment date was in excess of the conversion price, the Company recorded a beneficial conversion feature of $ 50,000 related to this note that was credited to additional paid in capital and reduced the carrying amount. At the commitment date, the actual intrinsic value of the beneficial conversion feature was approximately $ 203,000 . The discount recorded is being amortized to interest expense over the life of the loan using the straight-line method. The obligations of the Company under the Note are secured by a senior lien and security interest in all of the assets of the Company and certain of its wholly-owned subsidiaries pursuant to the terms and conditions of a Security Agreement dated June 26, 2020 by the Company in favor of the noteholder. In connection with the issuance of the Note, the holders of the secured promissory notes that the Company issued to select accredited investors between June 28, 2019 and August 5, 2019 in the aggregate principal amount of approximately $ 5.7 On January 27, 2022, the conversion price of the note was adjusted to the lower of 65% 0.78 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) For both the three and nine-month periods ended September 30, 2022 and September 31, 2021 the Company recognized approximately $ 2,700 7,900 As of September 30, 2022, the Company remains in default on the repayment of principal of $ 58,055 23,500 140% The 40% premium will be recorded once a demand occurs. Secured Convertible Promissory Note – October 2020 On October 30, 2020, the Company issued to an existing investor in and lender to the Company a 10% 111,111 100,000 1.40 70% 1.00 The obligations of the Company under the note are secured by a senior lien and security interest in all of the assets of the Company. The Company recorded approximately $ 9,000 The interest rate on the note was 10% 18% Additionally, the Company issued the noteholder 79,366 1.60 1.00 47,619 57,000 0.16% 262.27% 0.92 The Company recorded a discount related to the warrants of approximately $ 66,000 6,000 5,000 45,000 69,000 5,000 4,000 On January 27, 2022, the exercise price of the notes and warrants was adjusted from the default conversion price of $ 0.98 0.78 35,816 As of September 30, 2022, 162,800 0.78 For the three and nine months ended September 30, 2022, the Company recognized approximately $ 5,100 and $ 15,200 in interest expense for the note, respectively. For the three and nine months ended September 30, 2021, the Company recognized approximately $ 5,000 and $ 14,800 in interest expense including $ 0 and $ 2,600 related to the amortization of debt issuance costs, respectively. For the three and nine-month period ended September 30, 2021, the Company recognized $ 0 and $ 79,000 and related to the amortization of debt discount. As of September 30, 2022, the debt discount and issuance costs for the note were fully amortized. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) As of September 30, 2022, the Company has outstanding principal of $ 111,111 34,400 As of September 30, 2022, the Company remains in default on the repayment of principal and interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125% The 25% premium will be recorded once a demand occurs Secured Convertible Promissory Note – January 202 On January 31, 2021, the Company issued to an existing investor in and lender to the Company a 10% 52,778 47,500 5,278 1.40 70% The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company. Additionally, the Company issued to the investor 37,699 warrants to purchase the Company’s common stock at an exercise price of $ 1.60 per share subject to certain adjustments as defined in the agreement. Until the Notes are no longer outstanding, the warrants have full-ratchet protection, are exercisable for a period of five years, and contain customary exercise limitations. On March 19, 2021, the exercise price of the warrants was adjusted to $ 1.00 and the Company issued an additional 22,619 warrants to the note holder. The Company recorded approximately $ 27,000 as a deemed dividend upon the repricing based upon the change in fair value of the warrants using a binomial valuation model. The Company used a risk-free rate of 0.16% , volatility of 262.27% , and expected term of 0.97 years in calculating the fair value of the warrants. The Company recorded approximately $ 2,000 The interest rate on the note was 10% 18% The Company recorded a discount related to the warrants of approximately $ 32,000 3,000 1,000 0.45% 240.83% The Company also recorded a debt discount related to the convertible debt of approximately $ 2,000 1,000 Total discounts recorded including the original issue discount were approximately $ 35,000 On January 27, 2022, the exercise price of the notes and warrants was adjusted from the default conversion price of $ 0.98 0.78 17,012 As of September 30, 2022, 77,330 For the three and nine months ended September 30, 2022, the Company recognized approximately $ 2,400 7,200 2,900 5,700 100 700 5,600 34,000 As of September 30, 2022, the debt discount and issuance costs on the note were fully amortized. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) As of September 30, 2022, the Company has outstanding principal of $ 52,778 13,900 As of September 30, 2022, the Company remains in default on the repayment of principal and accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125% The 25% premium will be recorded once a demand occurs. Secured Convertible Promissory Note – April 2021 On April 12, 2021, the Company issued to an accredited investor in and lender to the Company a 10% 66,667 60,000 6,667 40,000 five 1.90 The note matured on October 12, 2021. Prior to default, interest accrued on the aggregate unconverted and then outstanding principal amount of the note at the rate of 10% 18% The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $ 1.50 70% The Company recorded a discount related to the warrants of approximately $ 34,000 3,700 3,000 0.89% 240.64% one On June 25, 2021, the exercise price of the warrants was adjusted to $ 1.50 10,667 11,000 0.92% 247.52% 0.96 On November 4, 2021, the Company issued 7,662 12,500 On November 30, 2021, the exercise price of the warrants was adjusted to $ 1.00 1.00 19,084 On January 27, 2022, the exercise price of the note and warrants was adjusted from the default conversion price of $ 1.05 0.78 0.78 16,147 As of September 30, 2022, 73,398 0.78 During the three-months ended September 30, 2022, the Company repaid $ 25,000 19,500 For the three and nine months ended September 30, 2022, the Company recognized approximately $ 1,800 and $ 7,800 in interest expense for the notes. For the three and nine-month period ended September 30, 2021, the Company recognized approximately $ 19,000 35,000 1,700 3,200 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) As of September 30, 2022, the Company has recorded $ 41,667 13,900 As of September 30, 2022, the Company remains in default on the repayment of principal and accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125% The 25% premium will be recorded once a demand occurs Secured Convertible Promissory Note – June 2021 On June 25, 2021, the Company issued to an accredited investor in and lender to the Company a 5% original issue discounted Senior Secured Convertible Promissory Note with a principal amount of $ 66,500 , for a purchase price of $ 63,000 , net of an original issue discount of $ 3,500 . Additionally, the Company issued to the investor 40,000 three -year warrants to purchase the Company’s common stock at an exercise price of $ 1.90 per share. Upon subsequent down-round equity sales by the Company, the number of shares issuable upon exercise of the Warrant shall be proportionately adjusted such that the aggregate exercise price of this Warrant shall remain $ 76,000 which is a full ratchet price protection provision. The note matured on June 25, 2022 10% The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $ 1.50 1.60 65% The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company. The Company incurred approximately $ 9,300 The Company also issued 2,377 5,040 Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 102,823 87,039 15,784 Total discounts recorded were $ 66,500 3,500 9,300 37,916 15,784 0.48% 302.11% 0.60 On August 11, 2021, the exercise price of the warrants was adjusted to $ 1.50 10,667 25,000 0.81 209 0.57 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) On October 27, 2021, the Company and the institutional investor who holds the convertible promissory note agreed to extend the maturity date of the note by six months to December 25, 2022 for no consideration. On November 30, 2021, the exercise price of the warrants was adjusted to $ 1.00 1.00 25,333 On January 27, 2022, the holder of the June 25, 2021, convertible note converted $ 9,500 421 0.78 12,721 28,000 18,000 23,000 23,000 5,000 0.78 21,436 As of September 30, 2022, 97,436 0.78 For the three and nine months ended September 30, 2022, the Company recognized approximately $ 10,000 29,600 3,400 10,400 30,810 3,000 As of September 30, 2022, the Company has recorded $ 57,000 15,700 9,100 Convertible Promissory Note – August 11, 2021 On August 11, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the investor its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $ 220,500 40,000 210,000 10,500 5,000 The note matured on August 11, 2022 10% 1.50 1.60 65% 24% ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold. The warrants are initially exercisable for a period of five years at a price of $ 1.90 per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the warrant. The Company incurred approximately $ 30,000 The Company also issued 7,000 Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 340,893 234,388 106,505 The Company recorded a total debt discount of $ 220,500 10,500 56,454 30,000 17,041 106,505 The fair value of the warrants on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.81% 253% On November 30, 2021, the exercise price of the warrants was adjusted to $ 1.00 1.00 36,000 On January 27, 2022, the conversion price of the notes was adjusted to the lower of $ 0.78 per share, or provided that if the average closing price of the Company’s common stock during any six consecutive trading days is below $1.60, the conversion price shall be reduced to 65% of the lowest trading price during the 20 consecutive trading days immediately preceding the conversion date. In addition, the exercise price of the warrant was adjusted to $ 0.78 per share and the Company issued an additional 21,436 warrants to the holder of the note. Both the conversion price of the note and warrants were adjusted as a result of a convertible note exercise at $ 0.78 per share. On May 12, 2022, the Company repaid $ 135,695 64,305 54,278 September 30, 2022 128,502 45,200 As of September 30, 2022, 97,436 0.78 For the three and nine months ended September 30, 2022, the Company recognized approximately $ 39,900 134,000 6,800 92,000 67,000 30,810 3,000 As of September 30, 2022, the Company has remaining $ 85,000 43,700 Convertible Promissory Note – August 17, 2021 On August 17, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the investor its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $ 220,500 40,000 210,000 10,500 5,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) The note matures on August 17, 2022 10% 1.50 1.60 65% In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold. The Warrants are initially exercisable for a period of five years at a price of $ 1.90 per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the Warrant. The Company incurred approximately $ 30,000 5,631 Due to the variability in the conversion price of the Note, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 398,404 297,833 100,571 The Company recorded a total debt discount of $ 220,500 10,500 62,220 30,000 17,209 100,571 The fair value of the warrants on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.77% 254% On October 27, 2021, the Company and the institutional investor who holds the promissory note agreed to extend the maturity date the notes by Nine months to February 17, 2023 for no consideration. On November 15, 2021, the Company defaulted on certain covenants in the note and the interest rate on the note reset to 24% On November 30, 2021, the exercise price of the warrants was adjusted to $ 1.00 1.00 36,000 On January 27, 2022, the conversion price of the notes was adjusted to the lower of $ 0.78 1.60 65% 0.78 21,436 0.78 As of September 30, 2022, 97,436 0.78 For the three and nine months ended September 30, 2022, the Company recognized approximately $ 35,400 105,000 12,700 37,700 27,200 2,700 As of September 30, 2022, the Company has recorded $ 220,500 53,100 52,800 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) Convertible Promissory Note – October 4, 2021 On October 4, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the Buyer a 10 131,250 23,810 110,000 2,977 The Note is due October 4, 2022. The Note provides for interest at the rate of 10 1.50 The warrants are exercisable for three-years from October 4, 2021, at an exercise price of $ 1.90 45,238 The Company incurred approximately $ 15,000 2,173 Due to insufficient authorized shares, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 564,943 487,052 77,891 The Company recorded a total debt discount of $ 131,250 6,250 15,000 32,109 77,891 On January 2, 2022, the Company defaulted on certain covenants contained in the October 4, 2021, convertible note and the interest rate reset to 16% On January 27, 2022, the exercise price of the note was adjusted to $ 0.78 0.78 On May 12, 2022, the Company repaid $ 83,500 2,977 1,000 11,571 8,428 81,700 For the three months ended September 30, 2022, the Company repaid $ 19,471 476 14,800 As of September 30, 2022, 23,810 1.90 For the three and nine months ended September 30, 2022, the Company recognized approximately $ 33,100 98,200 500 5,700 As of September 30, 2022, the Company has recorded $ 16,708 1,100 Convertible Promissory Note – October 7, 2021 On October 7, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the investor a 10% 131,250 23,810 110,000 2,977 2,632 The Note is due October 7, 2022. The Note provides for interest at the rate of 10% 1.50 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) The Warrants are exercisable for six-years from October 7, 2021, at an exercise price of $ 1.90 45,238 The Company incurred approximately $ 15,000 Due to insufficient authorized shares, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 564,184 487,667 76,517 The Company recorded a total debt discount of $ 131,250 6,250 15,000 33,483 76,517 On January 5, 2022, the Company defaulted on certain covenants contained in the October 7, 2021, convertible note and the interest rate reset to 16% On January 27, 2022, the exercise price of the note was adjusted to $ 0.78 0.78 On May 12, 2022, the Company repaid $ 83,500 2,977 1,000 11,571 8,428 82,900 For the three months ended September 30, 2022, the Company repaid $ 19,471 476 15,200 As of September 30, 2022, 23,810 1.90 For the three and nine months ended September 30, 2022, the Company recognized approximately $ 33,100 98,200 500 5,800 As of September 30, 2022, the Company has recorded $ 16,708 2,200 Convertible Promissory Note – March 15, 2022 On March 15, 2022, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the investor a 10% 250,000 200,000 50,000 180,000 20,000 2,500 10,000 The Note provides for guaranteed interest at the rate of 10% 25,000 39,285.71 The Note is convertible into shares of common stock at any time following any event of default at the investor’s option at a conversion price of ninety percent (90%) per share of the lowest per-share trading price of the Company; stock during the ten trading day periods before the conversion, subject to certain adjustments. The Company recorded a total debt discount of $ 250,000 50,000 34,384 3,596 162,020 For the three months ended September 30, 2022, the Company repaid $ 67,176 11,396 42,600 For the three and nine months ended September 30, 2022, the Company recognized approximately $ 63,000 137,000 25,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) At September 30, 2022, the Company has recorded $ 182,800 13,600 113,000 Derivative Liabilities Pursuant to Convertible Notes and Warrants In connection with the issuance of the unrelated party convertible notes (collectively referred to as “Notes”) and warrants (collectively referred to as “Warrants”), discussed above, the Company determined that the terms of certain Notes contained an embedded conversion options to be accounted for as derivative liabilities due to the holder having the potential to gain value upon conversion and provisions which includes events not within the control of the Company. Due to the fact that the number of shares of common stock potentially issuable exceed the Company’s authorized share limit as of September 30, 2022, the equity environment was tainted and all convertible debentures and warrants were included in the value of the derivative. In accordance with ASC 815-40 – Derivatives and Hedging – Contracts in an Entity’s Own Stock For the nine-month period ended September 30, 2022, in connection with the issuance of the Notes and warrants, on the initial measurement dates, the fair values of the embedded conversion option of approximately $ 1,422,000 1,314,000 108,000 At the end of the period, the Company revalued the embedded conversion option derivative liabilities. In connection with the initial valuations and these revaluations, the Company recorded a gain from the initial and change in the derivative liabilities fair value of approximately $ 1,534 During the nine months period ended September 30, 2022, the fair value of the derivative liabilities was estimated at issuance and at September 30, 2022, using the Binomial Lattice valuation model with the following assumptions: Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode Dividend rate — % Term (in years) 0.0 1.07 Volatility 147 317.47 % Risk-free interest rate 1.28 4.25 % Other than the effect on the derivative valuation recognized in operations, there was no accounting effect to the ratchet adjustments of certain convertible notes to reduce the conversion price to $ 0.78 | Note 4 – Notes Payable and Convertible Promissory Notes 2019 Term Loan During 2019, the Company entered into term loan subscription agreements with certain accredited investors, pursuant to which the Company issued secured promissory notes in the aggregate principal amount of approximately $ 5.7 707,000 The promissory notes accrued interest at a rate of 12 15 The unpaid principal balance of the notes, plus accrued and unpaid interest thereon, matured on June 28, 2020 The Company recognized approximately $ 1.2 million in interest expense related to the 2019 Term Loan for the year ended December 31, 2020 including $ 347,000 related to the amortization of debt issuances costs. The Company recognized approximately $ 852,000 in interest expense related to the notes for the year ended December 31, 2021. As of December 31, 2021, the debt discount and issuance costs for this term loan were fully amortized. As of December 31, 2021, the Company had approximately $ 2.0 million of accrued interest on the notes included in accrued expenses and remains in default on the repayment of approximately $ 5.7 million in principal and $ 2.0 Convertible Promissory Notes The following table summarizes the Company’s outstanding convertible notes as of December 31, 2021, and December 31, 2020: Schedule of Convertible Promissory Notes (in thousands) December 31, 2021 December 31, 2020 Convertible Notes $ 1,516 $ 720 Unamortized discounts (530 ) (79 ) Convertible Notes Payable $ 986 $ 641 Eight convertible notes with outstanding principal of approximately $ 1.3 million were in default as of the issuance date of this Report. Secured Convertible Promissory Note – February 2020 On February 5, 2020, the Company entered into a Securities Purchase Agreement with accredited investors and issued the investors, (i) original issue discount Convertible Promissory Notes with a principal of $ 550,500 10 499,950 The Convertible Notes matured on August 5, 2020 . Prior to default, interest accrued to the Holders on the aggregate unconverted and then outstanding principal amount of the Notes at the rate of 10 % per annum, calculated on the basis of a 360-day year and accrues daily. On June 15, 2020, the Company defaulted on certain covenants in the 2020 term loan and the interest rate reset to the default rate of 18 %. Until the Convertible Notes are no longer outstanding, the Convertible Notes are convertible, in whole or in part, at any time, and from time to time, into shares of Common Stock at the option of the noteholder. The conversion price is the lower of: (i) $ 10.00 70 60 1.00 The exercise price of the Warrants shall be equal to the conversion price of the Convertible Notes, provided, that on the date that the Convertible Notes are no longer outstanding, the exercise price shall be fixed at the conversion price of the Convertible Notes on such date, with the exercise price of the Warrants thereafter (and the number of shares of Common Stock issuable upon the exercise thereof) being subject to adjustment as set forth in the Warrants. The warrants have a 5 The Company recorded a discount related to the Warrants of approximately $ 322,000 , which includes an allocation of original issue discount (“OID”) and issue costs of $ 30,000 and $ 53,000 based on the relative fair value of the instruments as determined by using the Monte-Carlo simulation model. The Company also recorded the remaining debt discount related to the convertible debt OID of approximately $ 21,000 and debt issuance costs of $ 38,000 using the relative fair value method to be amortized as interest expense over the term of the loan using the straight-line method. Total discounts recorded were approximately $ 381,000 . The Company recognized $ 75,000 381,000 38,000 96,000 On March 19, 2021, the holder of the Convertible Note converted $ 25,900 25,900 On July 29, 2021, the holder of the Convertible Note converted $ 27,500 27,500 On August 16, 2021, the holder of the Convertible Note converted $ 25,000 25,000 On September 13, 2021, the holder of the Convertible Note converted $ 32,500 32,500 On October 4, 2021, the holder of the Convertible Note converted $ 26,250 26,250 On November 29, 2021, the holder of the Convertible Note converted $ 31,150 31,151 The total note principal and interest converted during the year ended December 31, 2021, was $ 168,300 and 168,294 common shares issued were valued at fair value based on the quoted trading prices on the conversion dates aggregating approximately $ 554,000 resulting in a loss on debt extinguishment of $ 386,000 . In addition, derivative fair value of $ 245,000 relating to the portion of the Note converted was settled resulting in gain on extinguishment of approximately $ 245,000 . The net loss on extinguishment was approximately $ 141,000 . As of December 31, 2021, the Company had accrued interest on the February 2020 Convertible Note of approximately $ 101,000 As of December 31, 2021, the Company remains in default on the repayment of remaining principal of $ 457,359 and accrued interest on the February 2020 Convertible Notes. Upon demand for repayment at the election of the holder, the holder of the Convertible Note is due 140 % of the aggregate of outstanding principal, interest, and other expenses due in respect of this Convertible Note. The 40% premium will be recorded once a demand occurs. Secured Convertible Promissory Note – June 2020 On June 26, 2020, the Company issued to an existing investor in the Company a 10 % original issue discount Senior Secured Convertible Promissory Note with a principal of $ 58,055 , for a purchase price of $ 52,500 , net of the original issue discount of $ 5,555 . The Convertible Note matured on December 26, 2020 . Prior to default, interest accrued on the aggregate unconverted and then outstanding principal amount of the Note at the rate of 10 % per annum, calculated on the basis of a 360-day year. The Company incurred approximately $ 14,000 in debt issuance costs. On August 5, 2020, the Company defaulted on certain covenants in the loan and the interest rate reset to the default rate of 18 The Note is convertible, in whole or in part, into shares of common stock of the Company at the option of the noteholder at a conversion price of $ 0.40 65 50,000 203,000 The obligations of the Company under the Note are secured by a senior lien and security interest in all of the assets of the Company and certain of its wholly-owned subsidiaries pursuant to the terms and conditions of a Security Agreement dated June 26, 2020 by the Company in favor of the noteholder. In connection with the issuance of the Note, the holders of the secured promissory notes that the Company issued to select accredited investors between June 28, 2019 and August 5, 2019 in the aggregate principal amount of approximately $ 5.7 For the year ended December 31, 2020, the Company recognized approximately $ 5,000 70,000 14,000 11,000 As of December 30, 2021, the Company remains in default on the repayment of principal of $ 58,055 16,000 140 The 40% premium will be recorded once a demand occurs Secured Convertible Promissory Note – October 2020 On October 30, 2020, the Company issued to an existing investor in and lender to the Company a 10 111,111 100,000 1.40 70 1.00 The obligations of the Company under the note are secured by a senior lien and security interest in all of the assets of the Company. The Company recorded approximately $ 9,000 The interest rate on the note was 10 18 Additionally, the Company issued the noteholder 79,366 1.00 47,619 57,000 0.16 262.27 0.92 The Company recorded a discount related to the warrants of approximately $ 66,000 , Including a discount of $ 6,000 and issuance costs of $ 5,000 based on the relative fair value of the instruments as determined by using the Black-Scholes valuation model. The Company recorded a beneficial conversion feature of $ 45,000 related to the note that was credited to additional paid in capital and reduced the carrying amount. The discount recorded is being amortized to interest expense over the life of the loan using the straight-line method. At the commitment date, the actual intrinsic value of the beneficial conversion feature was approximately $ 69,000 . The Company also recorded a debt discount related to the convertible debt of approximately $ 5,000 and debt issuance cost of $ 4,000 using the relative fair value method to be amortized as interest expense over the term of the loan using the straight-line method. For the year ended December 31, 2020, the Company recognized approximately $ 2,000 in interest expense. For the year ended December 31, 2020, the Company recognized $ 41,300 related to the amortization of debt discount including $ 1,300 of debt issuance costs. For the year ended December 31, 2021, the Company recognized approximately $ 17,000 in interest expense. For the year ended December 31, 2021, the Company recognized $ 79,000 related to the amortization of debt discount including debt issuance costs. As of December 31, 2021, the Company has outstanding principal of $ 111,111 19,000 As of December 31, 2021, the Company remains in default on the repayment of principal and interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125 The 25% premium will be recorded once a demand occurs Secured Convertible Promissory Note – January 2021 On January 31, 2021, the Company issued to an existing investor in and lender to the Company a 10 52,778 47,500 5,278 1.40 70 The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company. Additionally, the Company issued to the investor 37,699 1.60 1.00 22,619 27,000 0.16 262.27 0.97 The Company recorded approximately $ 2,000 The interest rate on the note was 10 18 The Company recorded a discount related to the warrants of approximately $ 32,000 3,000 1,000 0.45 240.83 one year The Company also recorded a debt discount related to the convertible debt of approximately $ 2,000 1,000 Total discounts recorded including the original issue discount were approximately $ 35,000 For year ended December 31, 2021, the Company recognized approximately $ 6,700 35,000 As of December 31, 2021, the Company has outstanding principal of $ 52,778 on the note, and has recorded approximately $ 6,700 of accrued interest included in accrued expenses on the accompanying balance sheet. As of December 31, 2021, the Company remains in default on the repayment of principal and accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125 The 25% premium will be recorded once a demand occurs Secured Convertible Promissory Note – April 2021 On April 12, 2021, the Company issued to an accredited investor in and lender to the Company a 10 66,667 60,000 6,667 40,000 five The note matured on October 12, 2021 , Prior to default, interest accrued on the aggregate unconverted and then outstanding principal amount of the note at the rate of 10 % per annum, calculated on-the-basis of a 360-day year. On October 12, 2021, the Company defaulted on the note and the interest rate on the note reset to 18 % per annum. The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $ 1.50 70 The Company recorded a discount related to the warrants of approximately $ 34,000 3,700 3,000 0.89 240.64 one year On June 25, 2021, the exercise price of the warrants was adjusted to $ 1.50 10,667 11,000 0.92 247.52 0.96 On November 4, 2021, the Company issued 7,662 12,500 On November 30, 2021, the exercise price of the warrants was adjusted to $ 1.00 based on a note conversion at $ 1.00 and the Company issued an additional 19,084 warrants to the note holder. For the year ended December 31, 2021, the Company recognized approximately $ 6,100 37,500 As of December 31, 2021, the Company has recorded $ 66,667 6,100 As of December 31, 2021, the Company remains in default on the repayment of principal and accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125 The 25% premium will be recorded once a demand occurs Secured Convertible Promissory Note – June 2021 On June 25, 2021, the Company issued to an accredited investor in and lender to the Company a 5 % original issue discounted Senior Secured Convertible Promissory Note with a principal amount of $ 66,500 , for a purchase price of $ 63,000 , net of an original issue discount of $ 3,500 . Additionally, the Company issued to the investor 40,000 three -year warrants to purchase the Company’s common stock at an exercise price of $ 1.90 per share. Upon subsequent down-round equity sales by the Company, the number of shares issuable upon exercise of the Warrant shall be proportionately adjusted such that the aggregate exercise price of this Warrant shall remain $ 76,000 which is a full ratchet price protection provision. The note matures one year from issuance 10 The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $ 1.50 1.60 65 The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company. The Company incurred approximately $ 9,300 The Company also issued 2,377 shares of common stock as a commission fee to the investment banker. The fair value of the common stock which was approximately $ 5,040 was recorded as debt issuance expense. Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 102,823 87,039 15,784 Total discounts recorded were $ 66,500 3,500 9,300 37,916 15,784 0.48 302.11 0.60 On August 11, 2021, the exercise price of the warrants was adjusted to $ 1.50 10,667 25,000 0.81 209 0.57 On October 27, 2021, the Company and the institutional investor who holds the convertible promissory note agreed to extend the maturity date of the note by six months to December 25, 2022 for no consideration. On November 30, 2021, the exercise price of the warrants was adjusted to $ 1.00 1.00 and the Company issued an additional 25,333 warrants to the note holder. For the year ended December 31, 2021, the Company recognized approximately $ 27,800 5,800 At December 31, 2021, the Company has recorded $ 66,500 of outstanding principal and approximately $ 5,700 of accrued interest and $ 38,700 of unamortized discount and issuance expenses. Convertible Promissory Note – August 11, 2021 On August 11, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the investor its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $ 220,500 40,000 210,000 10,500 5,000 The note matured one year 10 % per annum, payable at maturity, and is convertible into common stock of the Company at a price of $ 1.50 per share, subject to anti-dilution adjustments in the event of certain corporate events as set forth in the Note, provided that if the average closing price of the Company’s common stock during any Nine consecutive trading days is below $1.60, the conversion price shall be reduced to 65 % of the lowest trading price during the 20 consecutive trading days immediately preceding the conversion date. On November 9, 2021, the Company defaulted on certain covenants in the note and the interest rate on the note reset to 24 % per annum. In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold. The Warrants are initially exercisable for a period of five years at a price of $ 1.90 per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the Warrant. The Company incurred approximately $ 30,000 The Company also issued 7,000 Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 340,893 234,388 106,505 The Company recorded a total debt discount of $ 220,500 10,500 56,454 30,000 17,041 106,505 The fair value of the warrants on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.81 253 one year On November 30, 2021, the exercise price of the warrants was adjusted to $ 1.00 based on a note conversion at $ 1.00 and the Company issued an additional 36,000 warrants to the note holder. For the year ended December 30, 2021, the Company recognized approximately $ 86,400 15,800 At December 31, 2021, the Company has remaining $ 220,500 15,800 134,100 Convertible Promissory Note – August 17, 2021 On August 17, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the investor its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $ 220,500 40,000 210,000 10,500 5,000 The note matures one year 10 1.50 1.60 65 In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold. The Warrants are initially exercisable for a period of five years at a price of $ 1.90 per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the Warrant The Company incurred approximately $ 30,000 5,631 Due to the variability in the conversion price of the Note, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 398,404 297,833 100,571 The Company recorded a total debt discount of $ 220,500 10,500 62,220 30,000 17,209 100,571 The fair value of the warrants on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.77 254 one year On October 27, 2021, the Company and the institutional investor who holds the promissory note agreed to extend the maturity date the notes by six months to February 17, 2023 for no consideration. On November 15, 2021, the Company defaulted on certain covenants in the note and the interest rate on the note reset to 24 On November 30, 2021, the exercise price of the warrants was adjusted to $ 1.00 based on a note conversion at $ 1.00 and the Company issued an additional 36,000 warrants to the note holder. For the year ended December 31, 2021, the Company recognized approximately $ 62,600 15,400 At December 31, 2021, the Company has recorded $ 220,500 15,400 157,900 Convertible Promissory Note – October 4, 2021 On October 4, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the Buyer a 10 % Convertible Redeemable Note in the principal amount of $ 131,250 and a six-year warrant to purchase 23,810 shares of common stock of the Company for which the Company received proceeds of $ 110,000 . In addition, the Company entered into a Registration Rights Agreement with the investor and issued the investor 2,977 common shares as a commitment fee. The Note is due October 4, 2022. The Note provides for interest at the rate of 10 % per annum, payable in seven equal monthly payments beginning on August 15, 2022 through the maturity date. The Note is convertible into shares of common stock at any time following the date of cash payment at the Buyer’s option at a conversion price of $ 1.50 per share, subject to certain adjustments. The Warrants are exercisable for three-years from October 4, 2021, at an exercise price of $ 1.90 per share, subject to certain adjustments, which exercise price may be paid on a cashless basis. The aggregate exercise price is $ 45,238 The Company incurred approximately $ 15,000 2,173 Due to the lack of authorized shares, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 564,943 with $ 487,052 charged to derivative expense and $ 77,891 recorded as a debt discount. The Company recorded a total debt discount of $ 131,250 6,250 15,000 32,109 77,891 For the year ended December 31, 2021, the Company recognized approximately $ 32,000 3,200 At December 31, 2021, the Company has recorded $ 131,250 3,200 99,200 Convertible Promissory Note – October 7, 2021 On October 7, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the investor a 10 % Convertible Redeemable Note in the principal amount of $ 131,250 and a three-year warrant to purchase 23,810 shares of common stock of the Company for which the Company received proceeds of $ 110,000 . In addition, the Company entered into a Registration Rights Agreement with the investor and issued the investor 2,977 common shares as a commitment fee and an additional 2,632 shares as a commission to the broker. The Note is due October 7, 2022. The Note provides for interest at the rate of 10 % per annum, payable at maturity. The Note is convertible into shares of common stock at any time following the date of cash payment at the Buyer’s option at a conversion price of $1.50 per share, subject to certain adjustments. The Warrants are exercisable for three-years from October 7, 2021, at an exercise price of $ 1.90 per share, subject to certain adjustments, which exercise price may be paid on a cashless basis. The aggregate exercise price is $ 45,238 The Company incurred approximately $ 15,000 in debt issuance costs. Due to the lack of authorized shares, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 564,184 with $ 487,667 charged to derivative expense and $ 76,517 recorded as a debt discount. The Company recorded a total debt discount of $ 131,250 6,250 33,483 76,517 For the year ended December 31, 2021, the Company recognized approximately $ 30,900 3,100 At December 31, 2021, the Company has recorded $ 131,250 3,100 100,300 Derivative Liabilities Pursuant to Convertible Notes and Warrants In connection with the issuance of the unrelated party convertible notes (collectively referred to as “Notes”) and warrants (collectively referred to as “Warrants”), discussed above, the Company determined that the terms of certain Notes and Warrants contain an embedded conversion options to be accounted for as derivative liabilities due to the holder having the potential to gain value upon conversion and provisions which includes events not within the control of the Company. Due to the fact that the number of shares of common stock issuable exceed the Company’s authorized share limit as of December 31, 2021, the equity environment was tainted and all convertible debentures and warrants were included in the value of the derivative. Accordingly, for existing embedded conversion options and existing warrants that were not previously accounted for as derivatives, the Company reclassified $ 3,462,000 Derivatives and Hedging – Contracts in an Entity’s Own Stock During the year ended December 31, 2021, in connection with the issuance of the Notes and Warrants, on the initial measurement dates, the fair values of the embedded conversion options of approximately $ 2.0 million was recorded as derivative liabilities of which $ 377,269 was allocated as a debt discount and $ 1,593,978 as derivative expense. At the end of the period, the Company revalued the embedded conversion option derivative liabilities. In connection with the initial valuations and these revaluations, the Company recorded a loss from the initial and change in the derivative liabilities fair value of approximately $ 4.1 million for the year ended December 31, 2021. During the year ended December 31, 2021, the fair value of the derivative liabilities was estimated at issuance and at the December 31, 2021, using the Binomial Lattice valuation model with the following assumptions: Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode Dividend rate — % Term (in years) 0.01 to 1 year Volatility 247 % to 412 % Risk-free interest rate 0.07 % to 1.26 % Other than the effect on the derivative valuation recognized in operations, there was no accounting effect to the ratchet adjustments of certain convertible notes to reduce the conversion price to $ 1.00 |
Licensing Agreements
Licensing Agreements | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Licensing Agreements | ||
Licensing Agreements | Note 5 - Licensing Agreements License of DiLA 2 On March 16, 2018, the Company entered into an exclusive sublicensing agreement for certain intellectual property rights to its DiLA2 delivery system. The agreement included an upfront payment of $ 200,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) | Note 5 - Licensing Agreements Les Laboratories Servier As a result of the Asset Purchase Agreement that the Company entered into with Symplmed Pharmaceuticals LLC in June 2017, Symplmed assigned to the Company an Amended and Restated License and Commercialization Agreement with Les Laboratories Servier, pursuant to which the Company has the exclusive right to manufacture, have manufactured, develop, promote, market, distribute and sell Prestalia® in the U.S. (and its territories and possessions). On January 4, 2021, the licensor terminated the licensing agreement with the Company for the commercialization of Prestalia®. No Novosom Agreements In 2010, the Company entered into an asset purchase agreement with Novosom Verwaltungs GmbH (“Novosom”), pursuant to which the Company acquired intellectual property for Novosom’s SMARTICLES-based liposomal delivery system. In May 2018, the Company issued to Novosom 2,599 shares of our common stock, with a fair value of $ 75,000 , as additional consideration pursuant to the Asset Purchase Agreement. Such shares were due to Novosom as a result of the receipt by our company of a license fee under the License Agreement that we entered into with Lipomedics Inc. in February 2017. On December 23, 2019, Novosom repurchased the acquired intellectual property for $ 45,000 of which $ 20,000 was payable upon execution of the agreement and $ 25,000 was to be paid upon the Company’s achievement of certain performance obligations by June 30, 2020. The Company recognized $ 45,000 No License of DiLA 2 On March 16, 2018, the Company entered into an exclusive sublicensing agreement for certain intellectual property rights to its DiLA2 delivery system. The agreement included an upfront payment of $ 200,000 |
Related Party Transactions
Related Party Transactions | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Related Party Transactions [Abstract] | ||
Related Party Transactions | Note 6 - Related Party Transactions Due to Related Party The Company and other related entities have had a commonality of ownership and/or management control, and as a result, the reported operating results and/or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous. The Company had a Master Services Agreement with Autotelic Inc., a related party that was partly owned by one of the Company’s former Board members and executive officers, namely Vuong Trieu, Ph.D., effective November 15, 2016. The Master Services Agreement terminated in 2018 with an unpaid balance for previous years services performed of approximately $4,000 is included in due to related party in the accompanying consolidated balance sheets at September 30, 2022, and December 31, 2021. In addition, as of September 30, 2022, and December 31, 2021, the Company owed various officers and directors approximately $ 1,000 $42,000 | Note 6 - Related Party Transactions Due to Related Party The Company and other related entities have had a commonality of ownership and/or management control, and as a result, the reported operating results and/or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous. The Company had a Master Services Agreement (“MSA”) with Autotelic Inc., a related party that is partly owned by one of the Company’s former Board members and executive officers, namely Vuong Trieu, Ph.D., effective November 15, 2016. The MSA stated that Autotelic Inc. would provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. Dr. Trieu resigned as a director of our company effective October 1, 2018. The Company and Autotelic Inc. agreed to terminate the MSA effective October 31, 2018. An unpaid balance for previous years services performed under the agreement of approximately $ 4,000 In addition, as of December 31, 2021, the Company owed various officers and directors approximately $ 42,000 |
Stockholders_ Equity
Stockholders’ Equity | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Equity [Abstract] | ||
Stockholders’ Equity | Note 7 - Stockholders’ Equity Preferred Stock Adhera has authorized 100,000 1,000 90,000 no 1,200 220 3,500 2,200 6,000 Series C Preferred Each share of Series C Preferred has a stated value of $ 5,000 per share, has a $ 5,100 liquidation preference per share, has voting rights of 33.33 votes per share , and is convertible into shares of common stock at a conversion price of $ 150.00 per share. As of September 30, 2022, and December 31, 2021, 100 Series D Preferred Each share of Series D Preferred has a stated value of $ 5,000 per share, has a liquidation preference of $ 300 per share, has voting rights of 62.5 votes per share and is convertible into shares of common stock at a conversion price of $ 80.00 per share. The Series D Preferred has a 5 % stated dividend rate when, and if declared by the Board of Directors, is not redeemable and has voting rights on an as-converted basis. As of September 30, 2022, and December 31, 2021, 40 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) Series E Convertible Preferred Stock and Warrants The Series E Preferred Stock has a stated value of $ 5,000 8 10.00 February 10, 2020 On March 19, 2021, the exercise price of the Series E warrants was adjusted from $ 10.00 1.00 25,900 25,900 390,000 0.16 262.27 .41 .43 As of May 17, 2021, the three-year anniversary of the closing of the Series E Preferred stock offering, all outstanding Series E Preferred stock were convertible by the Company into common stock. On June 8, 2021, an investor converted 8 10,000 5,051 2,679 3,750 On July 30, 2021, an investor converted 50 250,000 25,000 On October 4, 2021, the Company issued 12,777 20 27,770 On October 5, 2021, the Company issued 19,271 30 42,707 On October 8, 2021, the Company issued 2,571 4 5,707 On October 12, 2021, the Company issued 3,216 5 7,156 On November 23, 2021, the Company issued 9,665 15 21,649 On January 27, 2022, the exercise price of the Series E warrants was adjusted to $ 0.78 0.78 On May 17, 2022, the Company effected the conversion of 3,059 5.1 2,035,306 10.00 As of September 30, 2022, the Company had a total of 1,453,028 0.78 The Company had accrued dividends on the Series E Preferred stock of approximately $ 453,000 5.0 As of September 30, 2022, and December 31, 2021, there were 267 3,326 Series F Convertible Preferred Shares and Warrants The Series F Preferred Stock has a stated value of $ 5,000 8 10.00 February 10, 2020 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) On March 19, 2021, the exercise price of the Series F warrants was adjusted from $ 10.00 1.00 25,900 25,900 31,000 0.16 262.27 .46 .53 On October 15, 2021, the Company issued 1,853 3 3,521 As of November 9, 2021, three-year anniversary of the closing of the Series F Preferred stock offering, all outstanding Series F Preferred stock and accrued dividends became convertible by the Company into common stock upon written notification being provided by the Company to stockholders. On January 27, 2022, the exercise price of the Series F warrants was adjusted to $ 0.78 0.78 On May 17, 2022, the Company effected the conversion of 358 541,000 233,127 10.00 As of September 30, 2022, the Company had a total of 154,425 The Company had accrued dividends on the Series F Preferred stock of approximately $ 448,000 No At September 30, 2022 and December 31, 2021, there were zero 358 Series G Convertible Preferred Shares The Series G Preferred Stock has a stated value of $ 5,000 8 10.00 As of September 30, 2022, no Common Stock On June 8, 2021, an investor converted 8 10,000 5,051 On June 8, 2021, the Company issued 2,679 3,750 On July 30, 2021, and investor converted 50 250,000 25,000 On August 11, 2021, the Company issued 5,000 56,464 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) On August 18, 2021, the Company issued 5,000 62,220 On September 22, 2021, the Company issued 15,008 39,290 On October 4, 2021, the Company issued 12,777 shares of common stock upon the conversion of 20 shares Series E Preferred stock including accrued dividends of $ 27,770 . On October 4, 2021, the Company issued 2,977 10,859 On October 5, 2021, the Company issued 19,271 30 42,707 On October 8, 2021, the Company issued 2,571 4 5,707 On October 8, 2021, the Company issued 2,977 12,233 On October 12, 2021, the Company issued 3,216 5 7,156 On October 15, 2021, the Company issued 1,853 3 3,521 On November 4, 2021, the Company issued 7,662 250,000 On November 23, 2021, the Company issued 9,665 15 21,649 On December 6, 2021, the Company issued 4,805 18,745 During the twelve-month period ending December 31, 2021, the company issued 168,301 98,141 70,160 554,000 386,000 On January 27, 2022, the Company issued 12,721 9,500 422 28,000 18,000 23,000 23,000 5,000 On March 15, 2022, the Company issued 2,500 3,596 On March 15, 2022, the Company issued 10,000 14,384 On May 11, 2022, the Company issued 19,231 11,820 On May 17, 2022, the Company effected the conversion of 3,059 5.1 2,035,306 10.00 On May 17, 2022, the Company effected the conversion of 358 541,000 233,127 10.00 Treasury Stock On May 12, 2022, the Company repurchased 5,954 2,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) Warrants As of September 30, 2022, there were 5,192,652 0.88 Schedule of Stockholders’ Equity Note, Warrants or Rights Shares 2023 2024 2025 2026 2027 Series E Preferred Stock 1,520,280 1,520,280 - - - - Series F Preferred Stock 154,425 154,425 - - - - Bridge Loan 1,111,112 - - - - 1,111,112 Convertible Notes (CVN) 2,389,394 - 145,056 36,777,552 345,600 - Other 17,441 13 1,179 3,201 - - Total Warrants 5,192,652 1,674,718 3,236,550 1,899,917 345,600 1,111,112 Schedule of Warrants Shares Warrants as of December 31, 2021 3,731,263 Issued as a result of price adjustments on convertible notes 133,284 Variable quantity of warrants related to the February 2020 note 216,993 Warrants issued with 2022 Bridge Note 1,111,112 Warrants as of September 30, 2022 5,192,652 Warrants outstanding as of September 30, 2022, included 5,127,591 The intrinsic value of 5,192,652 2.5 As discussed in Note 2 above, the Company has issued convertible notes and warrants with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock and various default provisions related to the payment of the notes in Company stock. The number of shares of common stock to be issued under the convertible notes and warrants is based on the future price of the Company’s common stock. The number of shares of common stock potentially issuable upon conversion of the promissory notes are therefore, indeterminate. Due to the fact that the number of shares of common stock potentially issuable exceed the Company’s authorized share limit as of September 30, 2022, the equity environment was tainted and all convertible debentures and warrants were included in the value of the derivative as of that date. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the convertible notes were recorded as derivative liabilities. On September 30, 2022, the Company evaluated all outstanding warrants and due to reasons discussed above, all warrants outstanding were considered tainted and were therefore, accounted for as derivative liabilities. Other than the effect on the derivative valuation recognized in operations, there was no accounting effect to the ratchet adjustments of certain warrants to reduce the conversion price to $ 0.78 | Note 7 - Stockholders’ Equity Preferred Stock Adhera has authorized 100,000 shares of preferred stock for issuance and has designated 1,000 shares as Series B Preferred Stock (“Series B Preferred”) and 90,000 shares as Series A Junior Participating Preferred Stock (“Series A Preferred”). No shares of Series A Preferred or Series B Preferred are outstanding. In March 2014, Adhera designated 1,200 shares as Series C Convertible Preferred Stock (“Series C Preferred”). In August 2015, Adhera designated 220 shares as Series D Convertible Preferred Stock (“Series D Preferred”). In April 2018, Adhera designated 3,500 shares of Series E Convertible Preferred Stock (“Series E Preferred”). In July 2018, Adhera designated 2,200 shares of Series F Convertible Preferred Stock (“Series F Preferred”). In December 2019, Adhera designated 6,000 shares of Series G Convertible Preferred Stock (“Series G Preferred”). The Company plans to file a certificate of elimination with respect to the Series A and Series B stock and a certificate of decrease with respect to each of its Series C, D and F Preferred stock. As of December 31, 2021 the Company has not filed the certificate of elimination. Each subsequent authorization of Preferred Stock has liquidation preference over the previous Series. Series C Preferred Each share of Series C Preferred has a stated value of $ 5,000 per share, has a $ 5,100 liquidation preference per share, has voting rights of 33.33 votes per Series C Preferred share , and is convertible into shares of common stock at a conversion price of $ 150.00 per share. As of December 31, 2021, and December 31, 2020, 100 Series D Preferred Each share of Series D Preferred has a stated value of $ 5,000 per share, has a liquidation preference of $ 300 per share, has voting rights of 62.5 votes per Series D Preferred share and is convertible into shares of common stock at a conversion price of $ 80.00 per share. The Series D Preferred has a 5 % stated dividend rate when, and if declared by the Board of Directors, is not redeemable and has voting rights on an as-converted basis. As of December 31, 2021, and December 31, 2020, 40 Series E Convertible Preferred Stock and Warrants The Series E Preferred Stock has a stated value of $ 5,000 per share and accrues 8 % dividends per annum that are payable in cash or stock at the Company’s discretion. The Series E Preferred has voting rights, dividend rights, liquidation preferences, conversion rights at the option of the holder and anti-dilution rights. Series E Preferred stock is convertible into shares of common stock at $ 10.00 . Anti-dilution price protection on Series E Preferred stock expired on February 10, 2020 . Warrants issued with Series E Convertible Preferred Stock have anti-dilution price protection, are exercisable for a period of five years, and contain customary exercise limitations. On March 19, 2021, the exercise price of the Series E warrants was adjusted from $ 10.00 1.00 25,900 25,900 390,000 0.16 262.27 .41 .43 As of May 17, 2021, the three-year anniversary of the closing of the Series E Preferred stock offering, all outstanding Series E Preferred stock may be converted by the Company into common stock upon written notification being provided by the Company to stockholders. As of December 31, 2021, the Company has not provided notice of conversion to the holders of the Series E Preferred stock. On June 8, 2021, an investor converted 8 10,000 5,051 2,679 3,750 On July 30, 2021, an investor converted 50 250,000 25,000 On October 4, 2021, the Company issued 12,777 shares of common stock upon the conversion of 20 shares Series E Preferred stock including accrued dividends of $ 27,770 On October 5, 2021, the Company issued 19,271 shares of common stock upon the conversion of 30 shares of Series E Preferred stock including accrued dividends of $ 42,707 On October 8, 2021, the Company issued 2,571 shares of common stock upon the conversion of 4 shares of Series E Preferred stock including accrued dividends of $ 5,707 On October 12, 2021, the Company issued 3,216 shares of common stock upon the conversion of 5 shares of Series E Preferred stock including accrued dividends of $ 7,156 On November 23, 2021, the Company issued 9,665 shares of common stock upon the conversion of 15 shares of Series E Preferred stock including accrued dividends of $ 21,649 As of December 31, 2021, the Company had a total of 1,520,280 1.00. The Company had accrued dividends on the Series E Preferred stock of approximately $ 5.0 3.7 At December 31, 2021 and December 31, 2020, there were 3,326 3,458 Series F Convertible Preferred Shares and Warrants The Series F Preferred Stock has a stated value of $ 5,000 per share and accrues 8 % dividends per annum that are payable in cash or stock at the Company’s discretion. The Series F Preferred has voting rights, dividend rights, liquidation preferences, conversion rights at the holders option and anti-dilution rights. Series F Preferred stock is convertible into shares of common stock at $ 10.00 Anti-dilution price protection on Series F Preferred stock expired on February 10, 2020 . Warrants issued with Series F Convertible Preferred Stock have anti-dilution price protection, are exercisable for a period of five years, and contain customary exercise limitations. On October 30, 2019, the Company repurchased 20 shares of Series F Convertible Preferred Stock including accrued and unpaid dividends and warrants to purchase 7,500 shares of common stock for $ 100,000 from our former CEO pursuant to an amendment to the settlement agreement dated April 4, 2019. The Company also committed to purchase from such officer the remaining Series F Convertible Preferred Stock and related warrants held by such officer for $ 100,000 by not later than March 1, 2020. As of December 31, 2021, the Company had not repurchased the remaining shares. On March 19, 2021, the exercise price of the Series F warrants was adjusted from $ 10.00 1.00 25,900 25,900 31,000 0.16 262.27 .46 .53 On October 15, 2021, the Company issued 1,853 shares of common stock upon the conversion of 3 shares of Series F Preferred stock and including total accrued dividends of $ 3,521 As of November 9, 2021, three-year anniversary of the closing of the Series F Preferred stock offering, all outstanding Series F Preferred stock and accrued dividends became convertible by the Company into common stock upon written notification being provided by the Company to stockholders. As of December 31, 2021, the Company has not provided notice of conversion to the holders of the Series F Preferred stock. As of December 31, 2021, the Company had a total of 154,425 The Company had accrued dividends on the Series F Preferred stock of approximately $ 488,000 347,000 At December 31, 2021 and December 31, 2020, there were 358 361 Series G Convertible Preferred Shares The Series G Preferred Stock has a stated value of $ 5,000 8 10.00 As of December 31, 2021, no Common Stock On December 11, 2020, the Company issued 6,085 10 60,850 On December 21, 2020, the Company issued 6,074 10 60,740 On June 8, 2021, an investor converted 8 10,000 5,051 On June 8, 2021, the Company issued 2,679 shares of common stock to the investor for a cashless exercise of 3,750 warrants. On July 30, 2021, and investor converted 50 250,000 25,000 On August 11, 2021, the Company issued 5,000 56,464 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) On August 18, 2021, the Company issued 5,000 62,220 On September 22, 2021, the Company issued 15,008 39,290 On October 4, 2021, the Company issued 12,777 20 27,770 On October 4, 2021, the Company issued 2,977 10,859 On October 5, 2021, the Company issued 19,271 30 42,707 On October 8, 2021, the Company issued 2,571 4 5,707 On October 8, 2021, the Company issued 2,977 12,233 On October 12, 2021, the Company issued 3,216 5 7,156 On October 15, 2021, the Company issued 1,853 3 3,521. On November 4, 2021, the Company issued 7,662 12,500 On November 23, 2021, the Company issued 9,665 15 21,649 On December 6, 2021, the Company issued 4,805 18,745 During the twelve-month period ending December 31, 2021, the company issued 168,294 common shares upon the conversion of $ 98,141 principal and $ 70,160 of accrued interest on the February 2020 convertible note. The common shares issued upon conversions of the note for the period ended December 31, 2021 were valued at fair value based on the quoted trading prices on the conversion dates aggregating approximately $ 554,000 resulting in a loss on debt extinguishment of approximately $386,000 . Warrants As of December 31, 2021, there were 3,731,263 1.0 Schedule of Stockholders’ Equity Note, Warrants or Rights Warrant Summary: Shares 2023 2024 2025 2026 Issued with Series E Preferred Stock 1,520,280 1,520,280 — — — Issued with Series F Preferred Stock 154,425 154,425 — — — Issued with Convertible Notes 2,039,117 — 123,620 1,645,930 269,567 Other 17,441 504 16,775 162 — Total Warrants 3,731,263 1,675,209 140,395 1,646,092 269,567 The above includes 3,713,822 price adjustable warrants. The intrinsic value of 3,731,263 1,492,503 A total of 17,188 Series D warrants expired during the period ended December 31, 2021. In addition, there were 3,750 Series E warrants and 12,500 warrants issued with convertible notes exercised on a cashless basis for the twelve-month period ended December 31, 2021. As discussed in Note 2 above, the Company has issued convertible notes and warrants with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock and various default provisions related to the payment of the notes in Company stock. The number of shares of common stock to be issued under the convertible notes and warrants is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is therefore, indeterminate. Due to the fact that the number of shares of common stock issuable exceed the Company’s authorized share limit as of December 31, 2021, the equity environment was tainted and all convertible debentures and warrants were included in the value of the derivative as of that date. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the warrants were recorded as derivative liabilities. On December 31, 2021, the Company evaluated all outstanding warrants to determine whether these instruments are tainted and, due to reasons discussed above, all warrants outstanding were considered tainted and were therefore, accounted for as derivative liabilities. |
Stock Incentive Plans
Stock Incentive Plans | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Share-Based Payment Arrangement [Abstract] | ||
Stock Incentive Plans | NOTE 8 - Stock Incentive Plans Stock Options The following table summarizes stock option activity for the nine-month period ended September 30, 2022: Schedule of Share Based Payments Arrangement, Option Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2021 19,203 $ 19.40 Options expired / forfeited (203 ) 34.00 Outstanding, September 30, 2022 19,000 19.60 Exercisable, September 30, 2022 19,000 $ 19.60 No The following table summarizes additional information on the Company’s stock options outstanding at September 30, 2022: Schedule of Share Based Payment Arrangement, Option, Exercise Price Range Options Outstanding Options Exercisable Exercise Price Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price 19.60 19,000 0.59 $ 19.60 19,000 $ 19.60 Totals 19,000 0.59 $ 19.60 19,000 $ 19.60 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) As of September 30, 2022, the Company had no No As of September 30, 2022, the intrinsic value of options outstanding or exercisable was zero there were no options outstanding with an exercise price less than the closing market price of our common stock at that date. | NOTE 8 - Stock Incentive Plans Stock Options The following table summarizes stock option activity for the year ended December 31, 2021 and 2020: Schedule of Share Based Payments Arrangement, Option Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2019 203,568 $ 11.60 Options expired / forfeited (184,000 ) $ 10.60 Outstanding, December 31, 2020 19,568 $ 20.00 Options expired / forfeited (365 ) $ 36.60 Outstanding, December 31, 2021 19,203 $ 19.40 Exercisable, December 31, 2021 19.203 $ 19.40 No stock options were granted during the years ended December 31, 2020 or 2021. The following table summarizes additional information on the Company’s stock options outstanding at December 31, 2021: Schedule of Share Based Payment Arrangement, Option, Exercise Price Range Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 19.60 19,000 1.33 $ 19.60 19,000 $ 19.60 $ 34.00 203 0.02 $ 34.00 203 $ 34.00 Totals 19,203 1.32 $ 19.75 19,203 $ 19.75 No stock options were issued by the Company during the year ended December 31, 2021. As of December 31, 2021, the Company had no unrecognized compensation expense related to unvested stock options. Total expense related to stock options was zero 8,000 As of December 31, 2021, the intrinsic value of options outstanding or exercisable was zero there were no options outstanding with an exercise price less than $ 1.40 |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | ||
Commitments and Contingencies | NOTE 9 - Commitments and Contingencies Litigation Because of the nature of the Company’s business, it is subject to claims and/or threatened legal actions, which arise out of the normal course of business. As of the date of this filing, the Company is not aware of any pending lawsuits against it, its officers or directors. Leases The Company does not own or lease any real property or facilities that are material to its current business operations. If the Company continues its business operations, the Company may seek to lease facilities to support its operational and administrative needs. Licensing Agreement – MLR 1019 On July 28, 2021, the Company and Melior II entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use Melior II’s Patents and know-how to develop products in consideration for cash payments up to approximately $ 21.8 5 The license agreement terminates upon the last expiration of the patents licensed by the Company, which is presently 2038 subject to any potential extensions and renewals of any of such patents. If the Company fails to have its common stock listed on Nasdaq or the NYSE (an “Uplisting Event”) within 12 months after the Company receives a Clinical Trial Authorization from the European Medicines Agency, then the Company’s commercial license and rights for using Melior II’s data shall terminate. Additionally, if the Company has completed the necessary steps to effect an Uplisting Event, the Company will have the option to purchase all rights held by Melior II on the MLR-1019 licensed products in consideration for 10 2.5 As of September 30, 2022, no performance milestones had been met under the agreement. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) Licensing Agreement – MLR 1023 On August 24, 2021, the Company as licensee entered into an exclusive license agreement with Melior I for the development, commercialization and exclusive license of Melior I’s MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes. Under the Agreement, the Company was granted an exclusive license to use the Melior I’s Patents and know-how to develop products in consideration for cash payments up to approximately $ 21.8 8 12 Under the original terms of the agreement if the Company failed to raise $4.0 million dollars within 120 days of the Effective Date of the agreement then the License would immediately terminate unless, by 120 Days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 Days would be provided to allow for the completion of the raise On October 20, 2021, the Company expanded the exclusive licensing agreement with Melior I to include two additional clinical indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation. On November 17, 2021, Melior I extended the Company’s timeline from 120 days to 180 days from the effective of the agreement for the Company to raise $4.0 million dollars unless, by 180 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising On February 16, 2022, an addendum to the licensing agreement dated August 4, 2021, was executed by the Company and Melior I, extending the requirement by the Company to raise $4.0 million dollars to June 16, 2022 On July 20, 2022, the Company entered into an addendum to the License Agreement for MLR-1023 with Melior I pursuant to which Melior I extended the license to February 1, 2023, in exchange for a $ 136,921 500,000 As of September 30, 2022, no performance milestones have been met under the agreement. | NOTE 9 - Commitments and Contingencies Litigation Because of the nature of the Company’s business, it is subject to claims and/or threatened legal actions, which arise out of the normal course of business. As of the date of this filing, the Company is not aware of any pending lawsuits against it, its officers or directors. Leases The Company does not own or lease any real property or facilities that are material to its current business operations. If the Company continues its business operations, the Company may seek to lease facilities in order to support its operational and administrative needs. Share Repurchase Agreement On October 30, 2019, the Company repurchased 20 7,500 100,000 100,000 Licensing Agreement – MLR 1019 On July 28, 2021, the Company and Melior Pharmaceuticals II, LLC (“MP”) entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments up to approximately $ 21.8 5 The license terminates upon the last expiration of the patents licensed by the Company, which is presently 2034 subject extensions and renewals of any of such patents. If the Company fails to have its common stock listed on Nasdaq or the NYSE (an “Uplisting Event”) within 12 months after the Company receives a Clinical Trial Authorization from the European Medicines Agency, then the Company’s commercial license and rights for using MP’s data shall terminate. Additionally, if the Company has completed the necessary steps to affect an Uplisting Event, the Company will have the option to purchase all rights held by MP on the MLR-1019 licensed products in consideration for 10 % of the outstanding shares of the Company’s common stock (immediately post Uplisting Event) and 2.5 % royalty of future gross product sales. As of December 31, 2021, no performance milestones had been met under the agreement. Licensing Agreement – MLR 1023 On August 24, 2021, the Company as licensee entered into an exclusive license agreement with Melior Pharmaceuticals I, Inc. for the development, commercialization and exclusive license of Melior’s MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes. Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments up to approximately $ 21.8 8 12 Under the original terms of the agreement if the Company failed to raise $4.0 million dollars within 120 days of the Effective Date then the License would immediately terminate unless, by 120 Days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 Days would be provided to allow for the completion of the raise On November 17, 2021, Melior Pharmaceuticals I, Inc. extended the Company’s timeline from 120 days to 180 days from the effective of the agreement for the Company to raise $4.0 million dollars unless, by 180 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising As of December 31, 2021, no performance milestones had been met under the agreement. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | NOTE 10 - Income Taxes The Company has identified its federal and California and Louisiana state tax returns as “major” tax jurisdictions. The periods the Company’s income tax returns are subject to examination for these jurisdictions are 2018 through 2021 for federal and 2019 through 2021 for Louisiana. The Company believes its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that would result in a material change to our financial position. Therefore, no liabilities for uncertain income tax positions have been recorded. At December 31, 2021, the Company had available net operating loss carry-forwards for federal income tax reporting purposes of approximately $ 326 The Company’s net deferred tax assets, deferred tax liabilities and valuation allowance as of December 31, 2021 and 2020 are summarized as follows: Schedule of Deferred Tax Assets and Liabilities (in thousands) 2021 2020 Years Ended December 31, (in thousands) 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 8,402 $ 7,741 Inventory reserve 114 Depreciation and amortization 1,272 2,226 Share based compensation 647 599 Other 613 297 Total deferred tax assets 10,935 10,977 Valuation allowance (10,935 ) (10,977 ) Net deferred tax assets — — Deferred tax liabilities: Intangible assets — — Net deferred tax liabilities $ — $ — The Company records a valuation allowance in the full amount of our net deferred tax assets since realization of such tax benefits has been determined by our management to be less likely than not. The valuation allowance decreased $ 42,000 0.6 As of the date of this filing, the Company has not filed its 2021 federal and state corporate income tax returns. The Company expects to file the 2021 return by the extension filing date. |
Subsequent Events
Subsequent Events | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Subsequent Events [Abstract] | ||
Subsequent Events | NOTE 10 – Subsequent Events Convertible Note Default(s) On October 4, 2022, the Company defaulted on the final payment on the October 4, 2021, convertible note. As a result of the default, the interest rate on the note reset to 16 On October 7, 2022, the Company defaulted on the final payment on the October 7, 2021, convertible note. As a result of the default, the interest rate on the note reset to 16 On October 15, 2022, the Company defaulted on the March 15, 2022 note. As a result of the default the interest rate on the note reset to 18 | NOTE 11 - Subsequent Events Default on Convertible Notes On January 2, 2022, the company defaulted on certain covenants contained in the October 4, 2021, convertible note and the interest rate reset to 16% On January 5, 2022, the company defaulted on certain covenants contained in the October 7, 2021, convertible note and the interest rate reset to 16% Conversion of Principal and Interest on Convertible Note On January 27, 2022, the holder of the June 25, 2021, convertible note converted $ 9,500 421 0.78 12,721 Amendment to Licensing Agreement On February 16, 2022, an addendum to the licensing agreement dated August 4, 2021, was executed by the Company and Melior Pharmaceuticals I, Inc, extending the requirement by the Company to raise $4.0 million dollars to June 16, 2022 Issuance of Convertible Promissory Note On March 15, 2022, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the Buyer a 10% Convertible Note in the principal amount of $ 250,000 for a purchase price of $ 200,000 reflecting a $ 50,000 original issue discount . The Company received total consideration of $ 180,000 after debt issuance costs of $ 20,000 . In addition, the Company issued 2,500 shares of common stock as a commitment fee to the investor. The company will record a debt discount related to the original issue discount and will evaluate the note terms for derivative accounting treatment. The Note provides for guaranteed interest at the rate of 10% per annum for the 12 months from and after the original issue date of the Note for an aggregate guaranteed interest of $ 25,000 , all of which guaranteed interest shall be deemed earned as of the date of the note. The principal amount and the guaranteed interest shall be due and payable in seven equal monthly payments each, $ 39,285.71 , commencing on August 15, 2022, and continuing on the 15th day of each month until paid in full not later than March 15, 2023, the maturity date. The Note is convertible into shares of common stock at any time following any event of default at the Buyer’s option at a conversion price of ninety percent (90%) per share of the lowest per-share trading price of the Company; stock during the ten trading day periods before the conversion, subject to certain adjustments. Reverse Stock Split On September 30, 2022, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the Delaware Secretary of State to effect a reverse stock split of all outstanding shares of the Company’s common stock at a ratio of 1-for-20 On October 5, 2022, the Company effected the 1-for-20 reverse stock split |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Accounting Policies [Abstract] | ||
Principles of Consolidation | Principles of Consolidation The consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive. | Principles of Consolidation The consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive. |
Going Concern and Management’s Liquidity Plans | Going Concern and Management’s Liquidity Plans The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2022, the Company had cash and cash equivalents of approximately $ 133,000 21.8 The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company recognized a net loss of approximately $ 1.8 1.3 55.4 In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for its our operations at terms acceptable to the Company or at all. General market conditions, as well as market conditions for companies in the Company’s financial and business position, as well as the ongoing issues arising from the COVID-19 pandemic, the Ukraine war and inflation and the Federal Reserve interest rate increases in response, and any recessionary environment or market downturns that could result, may make it difficult for the Company to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of its stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties. Reverse Stock-split On September 30, 2022, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the Delaware Secretary of State to effect a reverse stock split of all outstanding shares of the Company’s common stock at a ratio of 1-for-20. On October 5, 2022, the Company effected the 1-for-20 reverse stock split of its common stock. The reverse stock split did not cause an adjustment to the par value or the authorized shares of the common stock. As a result of the reverse stock split, the Company retroactively adjusted all outstanding common stock equivalents including options, warrants, convertible notes and other agreements with third parties. All disclosures of common shares and per common share data in the accompanying consolidated financial statements and related notes reflect the reverse stock split for all periods presented. As a result of the reverse split the Company recorded a $361,000 adjustment to the par value of common stock which was offset to additional paid-in capital. Summary of Significant Accounting Policies | Going Concern and Management’s Liquidity Plans The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2021, the Company had cash and cash equivalents of approximately $ 76,000 25.1 The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net loss of approximately $ 6.4 million for the year ended December 31, 2021 and used cash in operating activities of approximately $ 664,000 . The Company had an accumulated deficit of approximately $ 53.0 million as of December 31, 2021. In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for its our operations at terms acceptable to the Company or at all. General market conditions, as well as market conditions for companies in the Company’s financial and business position, as well as the ongoing issue arising from the COVID-19 pandemic, may make it difficult for the Company to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of its stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties. Summary of Significant Accounting Policies |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of six months or less at the time of purchase to be cash equivalents. As of December 31, 2021 and September 30, 2022, the Company had approximately $ 76,000 133,000 The Company deposits its cash with major financial institutions that may at times exceed the federally insured limit. As of December 31, 2021 and September 30, 2022, the Company did no 250,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) | Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. As of December 31, 2021, the Company had approximately $ 76,000 in cash equivalents. The Company deposits its cash with major financial institutions and may at times exceed the federally insured limit. At December 31, 2021, the Company’s cash balance did not exceed the federal insurance limit. |
Use of Estimates | Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances. | Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of September 30, 2022, the Company measured conversion features on outstanding convertible notes and warrants as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 7.3 million. The value of the derivative liability as of September 30, 2022, was determined by using the binomial lattice model using the following inputs: risk free rate of 4.05% to 4.25% , volatility of 147% to 317% and time to maturity of zero to one year no liabilities or assets measured at fair value on a non-recurring basis as of September 30, 2022. Schedule of Fair Value Measurements Fair Value Measurements at September 30, 2022 Quoted Other Significant (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liabilities $ - $ - $ 7,260 $ 7,260 Total $ - $ - $ 7,260 $ 7,260 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments (in thousands) Warrants Notes Total Nine-Months Ended September 30, 2022 (in thousands) Warrants Notes Total Balance at December 31, 2021 $ 5,336 $ 2,361 $ 7,697 Initial valuation of derivative liabilities included in debt discount 1,151 163 1,314 Initial valuation of derivative liabilities included in derivative expense — 108 108 Reclassification of derivative liabilities loss to gain on debt extinguishment — (325 ) (325 ) Change in fair value included in derivative expense (318 ) (1,216 ) (1,534 ) Balance at September 30, 2022 $ 6,169 $ 1,091 $ 7,260 ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments. | Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of December 31, 2021, the Company measured conversion features on outstanding convertible notes and warrants as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 7.7 million. The value of the derivative liability as of December 31, 2021, was determined by using the binomial lattice model using the following inputs: 0.069 % to 1.26 % risk free rate, volatility of 255 % to 399 % and time to maturity of 0 - 0.60 years. There were no liabilities or assets measured at fair value on a non-recurring basis as of December 31, 2021, and there were no liabilities or assets measured at fair value on a recurring or non-recurring basis as of December 31, 2020. Schedule of Fair Value Measurements (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurements at December 31, 2021 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 7,697 $ 7,697 Total $ - $ - $ 7,697 $ 7,697 A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments Year Ended December 31, 2021 (In thousands) Warrants Notes Total Balance at December 31, 2020 $ — $ — $ — Initial valuation of derivative liabilities included in debt discount — 377 377 Initial valuation of derivative liabilities included in derivative expense 246 1,348 1,594 Reclassification of derivative liabilities gain to loss on debt extinguishment (52 ) (193 ) (245 ) Reclass from additional paid-in capital 3,107 355 3,462 Change in fair value included in derivative expense 2,035 474 2,509 Balance at December 31, 2021 $ 5,336 $ 2,361 $ 7,697 ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments. |
Convertible Debt and Warrant Accounting | Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”), the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assesses whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet those requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position. Convertible debt – beneficial conversion feature Prior to the Company’s adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options Derivatives and Hedging—Contracts in Entity’s Own Equity Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) If the conversion feature does not qualify for derivative treatment, the convertible debt is treated as traditional debt. | Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”), the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assesses whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet those requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position. Convertible debt – beneficial conversion feature Prior to the Company’s adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options Derivatives and Hedging—Contracts in Entity’s Own Equity Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible debt is treated as traditional debt. |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements Recently Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements. In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic: 1. An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. 2. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: a. For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider: i. An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) ii. An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50. b. For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. 3. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows: a. A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs. b. A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest. c. Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year. The adoption by the Company as of January 1, 2022, did not have a significant impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures. | Recently Issued Accounting Pronouncements Recently Adopted In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements. Not Yet Adopted In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic: 1. An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. 2. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: a. For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider: i. An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments. ii. An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50. b. For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. 3. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows: a. A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs. b. A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest. c. Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures. |
Net Loss per Common Share | Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options, convertible notes and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) The following table presents the computation of net loss per share (in thousands), except share and per share data): Schedule of Earnings Per Share, Basic and Diluted 2022 2021 2022 2021 Three Months Ended Nine Months Ended 2022 2021 2022 2021 Numerator Net loss $ (1,804 ) $ (3,739 ) $ (1,779 ) $ (4,682 ) Dividends (8 ) (406 ) (574 ) (1,679 ) Net Loss allocable to common stockholders $ (1,812 ) $ (4,145 ) $ (2,353 ) $ (6,361 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 3,160,877 649,321 2,019,953 587,117 Net loss per share of common stock, basic and diluted Net loss per share $ (0.57 ) $ (6.38 ) $ (1.16 ) $ (10.83 ) The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 Nine-Months Ended September 30, 2022 2021 Stock options outstanding 19,000 19,378 Convertible notes 2,389,770 1,216,640 Warrants 5,192,652 3,065,318 Series C Preferred Stock 3,334 3,334 Series D Preferred Stock 2,500 2,500 Series E Preferred Stock 178,833 2,175,826 Series F Preferred Stock — 225,995 Total 7,786,089 6,708,991 | Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options, convertible notes and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted (in thousands except share and per share data) 2021 2020 December 31, (in thousands except share and per share data) 2021 2020 Numerator Net loss $ (6,351 ) $ (3,766 ) Preferred stock dividends (2,054 ) (1,540 ) Net Loss allocable to common stockholders $ (8,405 ) $ (5,306 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 654,700 548,514 Net loss per share of common stock, basic and diluted Net loss per share, basic and diluted $ (12.84 ) $ (9.67 ) The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 Year Ended December 31, 2021 2020 Stock options outstanding 19,203 19,568 Convertible notes 2,434,842 1,682,930 Warrants 3,731,263 3,909,100 Series C Preferred Stock 3,334 3,334 Series D Preferred Stock 2,500 2,500 Series E Preferred Stock 2,162,076 2,102,801 Series F Preferred Stock 227,761 215,199 Total 8,580,979 7,935,432 As of December 31, 2021, the Company’s fully diluted common stock equivalents exceeded the 180,000,000 shares currently authorized prior to the reverse stock split. (See Note 11) |
Stock-Based Compensation | Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised if and when a forfeiture becomes probable. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months Ended September 30, 2022 (Unaudited) | Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised if and when a forfeiture becomes probable. |
Income Taxes | Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. | Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. |
Basis of Presentation | Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The information furnished in this Report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the nine months ended September 30, 2022, are not necessarily indicative of the results for the year ending December 31, 2022, or for any future period. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Accounting Policies [Abstract] | ||
Schedule of Fair Value Measurements | Schedule of Fair Value Measurements Fair Value Measurements at September 30, 2022 Quoted Other Significant (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liabilities $ - $ - $ 7,260 $ 7,260 Total $ - $ - $ 7,260 $ 7,260 | Schedule of Fair Value Measurements (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurements at December 31, 2021 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 7,697 $ 7,697 Total $ - $ - $ 7,697 $ 7,697 |
Schedule of Roll Forward of Level 3 Financial Instruments | A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments (in thousands) Warrants Notes Total Nine-Months Ended September 30, 2022 (in thousands) Warrants Notes Total Balance at December 31, 2021 $ 5,336 $ 2,361 $ 7,697 Initial valuation of derivative liabilities included in debt discount 1,151 163 1,314 Initial valuation of derivative liabilities included in derivative expense — 108 108 Reclassification of derivative liabilities loss to gain on debt extinguishment — (325 ) (325 ) Change in fair value included in derivative expense (318 ) (1,216 ) (1,534 ) Balance at September 30, 2022 $ 6,169 $ 1,091 $ 7,260 | A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments Year Ended December 31, 2021 (In thousands) Warrants Notes Total Balance at December 31, 2020 $ — $ — $ — Initial valuation of derivative liabilities included in debt discount — 377 377 Initial valuation of derivative liabilities included in derivative expense 246 1,348 1,594 Reclassification of derivative liabilities gain to loss on debt extinguishment (52 ) (193 ) (245 ) Reclass from additional paid-in capital 3,107 355 3,462 Change in fair value included in derivative expense 2,035 474 2,509 Balance at December 31, 2021 $ 5,336 $ 2,361 $ 7,697 |
Schedule of Earnings Per Share, Basic and Diluted | The following table presents the computation of net loss per share (in thousands), except share and per share data): Schedule of Earnings Per Share, Basic and Diluted 2022 2021 2022 2021 Three Months Ended Nine Months Ended 2022 2021 2022 2021 Numerator Net loss $ (1,804 ) $ (3,739 ) $ (1,779 ) $ (4,682 ) Dividends (8 ) (406 ) (574 ) (1,679 ) Net Loss allocable to common stockholders $ (1,812 ) $ (4,145 ) $ (2,353 ) $ (6,361 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 3,160,877 649,321 2,019,953 587,117 Net loss per share of common stock, basic and diluted Net loss per share $ (0.57 ) $ (6.38 ) $ (1.16 ) $ (10.83 ) | The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted (in thousands except share and per share data) 2021 2020 December 31, (in thousands except share and per share data) 2021 2020 Numerator Net loss $ (6,351 ) $ (3,766 ) Preferred stock dividends (2,054 ) (1,540 ) Net Loss allocable to common stockholders $ (8,405 ) $ (5,306 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 654,700 548,514 Net loss per share of common stock, basic and diluted Net loss per share, basic and diluted $ (12.84 ) $ (9.67 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 Nine-Months Ended September 30, 2022 2021 Stock options outstanding 19,000 19,378 Convertible notes 2,389,770 1,216,640 Warrants 5,192,652 3,065,318 Series C Preferred Stock 3,334 3,334 Series D Preferred Stock 2,500 2,500 Series E Preferred Stock 178,833 2,175,826 Series F Preferred Stock — 225,995 Total 7,786,089 6,708,991 | The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 Year Ended December 31, 2021 2020 Stock options outstanding 19,203 19,568 Convertible notes 2,434,842 1,682,930 Warrants 3,731,263 3,909,100 Series C Preferred Stock 3,334 3,334 Series D Preferred Stock 2,500 2,500 Series E Preferred Stock 2,162,076 2,102,801 Series F Preferred Stock 227,761 215,199 Total 8,580,979 7,935,432 |
Notes Payable and Convertible_2
Notes Payable and Convertible Promissory Notes (Tables) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Debt Disclosure [Abstract] | ||
Schedule of Convertible Promissory Notes | The following table summarizes the Company’s outstanding convertible notes as of September 30, 2022, and December 31, 2021: Schedule of Convertible Promissory Notes (in thousands) September 30, 2022 December 31, 2021 Convertible Notes $ 1,300 $ 1,516 Unamortized discounts and fees (178 ) (530 ) Convertible notes payable, net $ 1,122 $ 986 | The following table summarizes the Company’s outstanding convertible notes as of December 31, 2021, and December 31, 2020: Schedule of Convertible Promissory Notes (in thousands) December 31, 2021 December 31, 2020 Convertible Notes $ 1,516 $ 720 Unamortized discounts (530 ) (79 ) Convertible Notes Payable $ 986 $ 641 |
Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode | During the nine months period ended September 30, 2022, the fair value of the derivative liabilities was estimated at issuance and at September 30, 2022, using the Binomial Lattice valuation model with the following assumptions: Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode Dividend rate — % Term (in years) 0.0 1.07 Volatility 147 317.47 % Risk-free interest rate 1.28 4.25 % | During the year ended December 31, 2021, the fair value of the derivative liabilities was estimated at issuance and at the December 31, 2021, using the Binomial Lattice valuation model with the following assumptions: Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode Dividend rate — % Term (in years) 0.01 to 1 year Volatility 247 % to 412 % Risk-free interest rate 0.07 % to 1.26 % |
Schedule of Outstanding Term Loans | The following table summarizes the Company’s outstanding term loans: Schedule of Outstanding Term Loans (in thousands) September 30, December 30, 2019 Term Loan $ 5,677 $ 5,677 2022 Term Loan 2,222 - Notes payable 7,899 5,677 Unamortized discounts (1,029 ) - Loans payable $ 6,870 $ 5,677 |
Stockholders_ Equity (Tables)
Stockholders’ Equity (Tables) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Equity [Abstract] | ||
Schedule of Stockholders’ Equity Note, Warrants or Rights | Schedule of Stockholders’ Equity Note, Warrants or Rights Shares 2023 2024 2025 2026 2027 Series E Preferred Stock 1,520,280 1,520,280 - - - - Series F Preferred Stock 154,425 154,425 - - - - Bridge Loan 1,111,112 - - - - 1,111,112 Convertible Notes (CVN) 2,389,394 - 145,056 36,777,552 345,600 - Other 17,441 13 1,179 3,201 - - Total Warrants 5,192,652 1,674,718 3,236,550 1,899,917 345,600 1,111,112 | Schedule of Stockholders’ Equity Note, Warrants or Rights Warrant Summary: Shares 2023 2024 2025 2026 Issued with Series E Preferred Stock 1,520,280 1,520,280 — — — Issued with Series F Preferred Stock 154,425 154,425 — — — Issued with Convertible Notes 2,039,117 — 123,620 1,645,930 269,567 Other 17,441 504 16,775 162 — Total Warrants 3,731,263 1,675,209 140,395 1,646,092 269,567 |
Schedule of Warrants | Schedule of Warrants Shares Warrants as of December 31, 2021 3,731,263 Issued as a result of price adjustments on convertible notes 133,284 Variable quantity of warrants related to the February 2020 note 216,993 Warrants issued with 2022 Bridge Note 1,111,112 Warrants as of September 30, 2022 5,192,652 |
Stock Incentive Plans (Tables)
Stock Incentive Plans (Tables) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Share-Based Payment Arrangement [Abstract] | ||
Schedule of Share Based Payments Arrangement, Option Activity | The following table summarizes stock option activity for the nine-month period ended September 30, 2022: Schedule of Share Based Payments Arrangement, Option Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2021 19,203 $ 19.40 Options expired / forfeited (203 ) 34.00 Outstanding, September 30, 2022 19,000 19.60 Exercisable, September 30, 2022 19,000 $ 19.60 | The following table summarizes stock option activity for the year ended December 31, 2021 and 2020: Schedule of Share Based Payments Arrangement, Option Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2019 203,568 $ 11.60 Options expired / forfeited (184,000 ) $ 10.60 Outstanding, December 31, 2020 19,568 $ 20.00 Options expired / forfeited (365 ) $ 36.60 Outstanding, December 31, 2021 19,203 $ 19.40 Exercisable, December 31, 2021 19.203 $ 19.40 |
Schedule of Share Based Payment Arrangement, Option, Exercise Price Range | The following table summarizes additional information on the Company’s stock options outstanding at September 30, 2022: Schedule of Share Based Payment Arrangement, Option, Exercise Price Range Options Outstanding Options Exercisable Exercise Price Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price 19.60 19,000 0.59 $ 19.60 19,000 $ 19.60 Totals 19,000 0.59 $ 19.60 19,000 $ 19.60 | The following table summarizes additional information on the Company’s stock options outstanding at December 31, 2021: Schedule of Share Based Payment Arrangement, Option, Exercise Price Range Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 19.60 19,000 1.33 $ 19.60 19,000 $ 19.60 $ 34.00 203 0.02 $ 34.00 203 $ 34.00 Totals 19,203 1.32 $ 19.75 19,203 $ 19.75 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Schedule of Deferred Tax Assets and Liabilities | The Company’s net deferred tax assets, deferred tax liabilities and valuation allowance as of December 31, 2021 and 2020 are summarized as follows: Schedule of Deferred Tax Assets and Liabilities (in thousands) 2021 2020 Years Ended December 31, (in thousands) 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 8,402 $ 7,741 Inventory reserve 114 Depreciation and amortization 1,272 2,226 Share based compensation 647 599 Other 613 297 Total deferred tax assets 10,935 10,977 Valuation allowance (10,935 ) (10,977 ) Net deferred tax assets — — Deferred tax liabilities: Intangible assets — — Net deferred tax liabilities $ — $ — |
Schedule of Fair Value Measurem
Schedule of Fair Value Measurements (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Defined Benefit Plan Disclosure [Line Items] | |||
Derivative liabilities | $ 7,260 | $ 7,697 | |
Total | 7,260 | 7,697 | |
Fair Value, Inputs, Level 1 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Derivative liabilities | |||
Total | |||
Fair Value, Inputs, Level 2 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Derivative liabilities | |||
Total | |||
Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Derivative liabilities | 7,260 | 7,697 | |
Total | $ 7,260 | $ 7,697 |
Schedule of Roll Forward of Lev
Schedule of Roll Forward of Level 3 Financial Instruments (Details) - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Short-Term Debt [Line Items] | ||
Balance at December 31, 2021 | $ 7,697 | |
Initial valuation of derivative liabilities included in debt discount | 1,314 | 377 |
Initial valuation of derivative liabilities included in derivative expense | 108 | 1,594 |
Reclassification of derivative liabilities loss to gain on debt extinguishment | (325) | (245) |
Reclass from additional paid-in capital | 3,462 | |
Change in fair value included in derivative expense | (1,534) | 2,509 |
Balance at September 30, 2022 | 7,260 | 7,697 |
Warrants [Member] | ||
Short-Term Debt [Line Items] | ||
Balance at December 31, 2021 | 5,336 | |
Initial valuation of derivative liabilities included in debt discount | ||
Initial valuation of derivative liabilities included in derivative expense | 246 | |
Reclassification of derivative liabilities loss to gain on debt extinguishment | (52) | |
Reclass from additional paid-in capital | 3,107 | |
Change in fair value included in derivative expense | 2,035 | |
Balance at September 30, 2022 | 5,336 | |
Convertible Notes [Member] | ||
Short-Term Debt [Line Items] | ||
Balance at December 31, 2021 | 2,361 | |
Initial valuation of derivative liabilities included in debt discount | 163 | 377 |
Initial valuation of derivative liabilities included in derivative expense | 108 | 1,348 |
Reclassification of derivative liabilities loss to gain on debt extinguishment | (325) | (193) |
Reclass from additional paid-in capital | 355 | |
Change in fair value included in derivative expense | (1,216) | 474 |
Balance at September 30, 2022 | 1,091 | 2,361 |
Warrant [Member] | ||
Short-Term Debt [Line Items] | ||
Balance at December 31, 2021 | 5,336 | |
Initial valuation of derivative liabilities included in debt discount | 1,151 | |
Initial valuation of derivative liabilities included in derivative expense | ||
Reclassification of derivative liabilities loss to gain on debt extinguishment | ||
Change in fair value included in derivative expense | (318) | |
Balance at September 30, 2022 | $ 6,169 | $ 5,336 |
Schedule of Earnings Per Share,
Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||
Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | ||||||||||
Net loss | $ (1,804) | $ 99 | $ (74) | $ (3,739) | $ (514) | $ (428) | $ (1,779) | $ (4,682) | $ (6,351) | $ (3,766) |
Dividends | (8) | (406) | (574) | (1,679) | (2,054) | (1,540) | ||||
Net Loss allocable to common stockholders | $ (1,812) | $ (4,145) | $ (2,353) | $ (6,361) | $ (8,405) | $ (5,306) | ||||
Weighted average common shares outstanding used to compute net loss per share, basic and diluted | 3,160,877 | 649,321 | 2,019,953 | 587,117 | 654,700 | 548,514 | ||||
Net loss per share | $ (0.57) | $ (6.38) | $ (1.16) | $ (10.83) | $ (12.84) | $ (9.67) |
Schedule of Antidilutive Securi
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Total | 7,786,089 | 6,708,991 | 8,580,979 | 7,935,432 |
Stock Options Outstanding [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Total | 19,000 | 19,378 | 19,203 | 19,568 |
Convertible Notes Payable [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Total | 2,389,770 | 1,216,640 | 2,434,842 | 1,682,930 |
Warrant [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Total | 5,192,652 | 3,065,318 | 3,731,263 | 3,909,100 |
Series C Preferred Stock [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Total | 3,334 | 3,334 | 3,334 | 3,334 |
Series D Preferred Stock [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Total | 2,500 | 2,500 | 2,500 | 2,500 |
Series E Preferred Stock [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Total | 178,833 | 2,175,826 | 2,162,076 | 2,102,801 |
Series F Preferred Stock [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Total | 225,995 | 227,761 | 215,199 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||
Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Property, Plant and Equipment [Line Items] | ||||||||||
Cash and cash equivalents | $ 133,000 | $ 133,000 | $ 76,000 | |||||||
Working capital | 21,800,000 | 21,800,000 | 25,100,000 | |||||||
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | 6,400,000 | |||||||||
Net cash used in operating activities | 1,262,000 | $ 369,000 | 664,000 | $ 588,000 | ||||||
Accumulated deficit | 53,000,000 | |||||||||
Cash Equivalents, at Carrying Value | 76,000 | |||||||||
Fair Value, Net Asset (Liability) | $ 0 | $ 0 | $ 0 | $ 0 | ||||||
Common Stock, Shares Authorized | 180,000,000 | 180,000,000 | 180,000,000 | 180,000,000 | ||||||
Net loss | $ 1,804,000 | $ (99,000) | $ 74,000 | $ 3,739,000 | $ 514,000 | $ 428,000 | $ 1,779,000 | $ 4,682,000 | $ 6,351,000 | $ 3,766,000 |
Accumulated deficit | 55,370,000 | 55,370,000 | 53,017,000 | 44,612,000 | ||||||
Cash equivalents | 133,000 | 133,000 | 76,000 | $ 1,000 | ||||||
Cash | 0 | 0 | 0 | |||||||
Cash federally insured limit amount | 250,000 | $ 250,000 | $ 250,000 | |||||||
Minimum [Member] | ||||||||||
Property, Plant and Equipment [Line Items] | ||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 4.05% | 0.069% | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate | 147% | 255% | ||||||||
Fair value assumptions, expected term | 0 years | |||||||||
Maximum [Member] | ||||||||||
Property, Plant and Equipment [Line Items] | ||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 4.25% | 1.26% | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate | 317% | 399% | ||||||||
Fair value assumptions, expected term | 1 year | 7 months 6 days | ||||||||
Fair Value, Inputs, Level 3 [Member] | ||||||||||
Property, Plant and Equipment [Line Items] | ||||||||||
Long-Term Debt, Fair Value | $ 7,300,000 | $ 7,300,000 | $ 7,700,000 |
Prepaid Expenses (Details Narra
Prepaid Expenses (Details Narrative) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Prepaid Expenses | |||
Prepaid expenses | $ 123,000 | $ 120,000 | $ 0 |
Schedule of Convertible Promiss
Schedule of Convertible Promissory Notes (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Debt Disclosure [Abstract] | |||
Convertible Notes | $ 1,300 | $ 1,516 | $ 720 |
Unamortized discounts and fees | (178) | (530) | (79) |
Convertible notes payable, net | $ 1,122 | $ 986 | $ 641 |
Schedule of Fair Value of Deriv
Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode (Details) | Sep. 30, 2022 | Dec. 31, 2021 |
Measurement Input, Expected Dividend Rate [Member] | ||
Short-Term Debt [Line Items] | ||
Risk-free interest rate | 0 | 0 |
Measurement Input, Expected Term [Member] | Minimum [Member] | ||
Short-Term Debt [Line Items] | ||
Term (in years) | 0 years | 3 days |
Measurement Input, Expected Term [Member] | Maximum [Member] | ||
Short-Term Debt [Line Items] | ||
Term (in years) | 1 year 25 days | 1 year |
Measurement Input, Price Volatility [Member] | Minimum [Member] | ||
Short-Term Debt [Line Items] | ||
Risk-free interest rate | 147 | 247 |
Measurement Input, Price Volatility [Member] | Maximum [Member] | ||
Short-Term Debt [Line Items] | ||
Risk-free interest rate | 317.47 | 412 |
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | ||
Short-Term Debt [Line Items] | ||
Risk-free interest rate | 1.28 | 0.07 |
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | ||
Short-Term Debt [Line Items] | ||
Risk-free interest rate | 4.25 | 1.26 |
Notes Payable and Convertible_3
Notes Payable and Convertible Promissory Notes (Details Narrative) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
May 12, 2022 USD ($) shares | May 11, 2022 USD ($) $ / shares shares | Mar. 15, 2022 USD ($) shares | Jan. 27, 2022 USD ($) $ / shares shares | Jan. 05, 2022 | Nov. 30, 2021 $ / shares shares | Nov. 29, 2021 USD ($) shares | Nov. 15, 2021 $ / shares shares | Nov. 15, 2021 $ / shares shares | Nov. 09, 2021 | Nov. 04, 2021 shares | Oct. 27, 2021 | Oct. 12, 2021 | Oct. 07, 2021 USD ($) $ / shares shares | Oct. 04, 2021 USD ($) $ / shares shares | Oct. 04, 2021 USD ($) $ / shares shares | Sep. 13, 2021 USD ($) shares | Aug. 17, 2021 USD ($) $ / shares shares | Aug. 16, 2021 USD ($) shares | Aug. 11, 2021 USD ($) $ / shares shares | Jul. 31, 2021 | Jul. 30, 2021 shares | Jul. 29, 2021 USD ($) shares | Jun. 25, 2021 USD ($) $ / shares shares | Apr. 12, 2021 USD ($) $ / shares shares | Mar. 19, 2021 USD ($) $ / shares shares | Jan. 31, 2021 USD ($) $ / shares shares | Oct. 30, 2020 USD ($) $ / shares shares | Aug. 05, 2020 | Jun. 26, 2020 USD ($) $ / shares | May 05, 2020 $ / shares | Feb. 05, 2020 USD ($) | Dec. 28, 2019 | Jul. 31, 2021 | Sep. 30, 2022 USD ($) $ / shares shares | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Sep. 30, 2021 USD ($) | Mar. 31, 2021 USD ($) | Sep. 30, 2022 USD ($) $ / shares shares | Sep. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) $ / shares shares | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Aug. 30, 2022 USD ($) | Jan. 31, 2022 $ / shares | Jan. 02, 2022 | Apr. 30, 2021 | Jan. 27, 2021 $ / shares | Jun. 15, 2020 | Oct. 30, 2019 $ / shares | Aug. 05, 2019 USD ($) | |
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 24% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | $ 551,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt payment Interest | $ 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable, current | $ 1,122,000 | 1,122,000 | 986,000 | $ 641,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 1,029,000 | 1,029,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 1,265,000 | 230,000 | 398,000 | 839,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Conversion instrument amount | 554,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Loss on extinguishment of debt | 386,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Loss on fair value of derivative liabilities | $ 1,425,000 | (3,055,000) | (4,103,000) | |||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 11,000 | $ 28,000 | $ 85,000 | $ 26,000 | 554,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible, beneficial conversion feature | 95,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 19,084 | 12,500 | 5,192,652 | 5,192,652 | 3,731,263 | |||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1 | $ 1.60 | $ 0.88 | $ 0.88 | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 7,899,000 | $ 7,899,000 | $ 5,677,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for warrants exercise | shares | 7,662 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | 77,330 | 77,330 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Reclassification of additional paid in capital to derivative liability | 3,462,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of Debt Issuance Costs | 328,000 | 72,000 | $ 101,000 | 114,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument description | (i) the 12-month anniversary of the original issuance date of the Notes, or May 11, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest. | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense related party | $ 21,000 | 25,000 | $ 66,800 | 76,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants or rights outstanding | shares | 5,192,652 | 5,192,652 | 3,731,263 | |||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | $ 92,000 | (177,000) | $ 307,000 | (177,000) | $ (141,000) | |||||||||||||||||||||||||||||||||||||||||||||||
Interest rate | 16% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 5,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 2,700 | 7,900 | 17,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 111,111 | $ 111,111 | $ 111,111 | $ 111,111 | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 9,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | 125% | 125% | 125% | ||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 2,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 1,300 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | $ 34,400 | $ 34,400 | $ 19,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 10% | 18% | ||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 1 | $ 1.40 | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 11 months 1 day | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 6,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 79,000 | $ 79,000 | 41,300 | |||||||||||||||||||||||||||||||||||||||||||||||||
Convertible note premium description | The 25% premium will be recorded once a demand occurs | The 25% premium will be recorded once a demand occurs | ||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible, beneficial conversion feature | 45,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Beneficial conversion feature | $ 69,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Threshold percentage | 70% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 35,816 | 47,619 | 79,366 | |||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ 57,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 1.60 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | October Two Thousand Twenty [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 5,100 | 5,000 | $ 15,200 | 14,800 | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 0 | 2,600 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt and warrant exercise price per share | $ / shares | $ 0.98 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt and warrant exercise price per share | $ / shares | $ 0.78 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | Valuation Technique, Option Pricing Model [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 6,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Unamortized debt issuance expense | 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.16 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 262.27 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 52,778 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 2,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 2,400 | 2,900 | 7,200 | 5,700 | $ 6,700 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 100 | 700 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | $ 13,900 | $ 13,900 | $ 6,700 | |||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable, current | $ 47,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 10% | 125% | 125% | 125% | ||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 1 | $ 1.40 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 11 months 19 days | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 2,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 5,600 | 34,000 | $ 35,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
Convertible note premium description | The 25% premium will be recorded once a demand occurs. | The 25% premium will be recorded once a demand occurs | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt default interest rate | 18% | 18% | ||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ 27,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion ratio | 0.70 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued | shares | 22,619 | 37,699 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1.60 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value method | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | 35,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 52,778 | $ 52,778 | $ 52,778 | |||||||||||||||||||||||||||||||||||||||||||||||||
Additional warrants issued | shares | 17,012 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt and warrant exercise price per share | $ / shares | $ 0.98 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt and warrant exercise price per share | $ / shares | 0.78 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | Investor and lender [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 5,278 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.16 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 262.27 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note April 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 66,667 | $ 41,667 | $ 41,667 | $ 66,667 | ||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | 125% | 125% | 125% | ||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Oct. 12, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | $ 1,800 | 1,700 | $ 7,800 | 3,200 | $ 6,100 | |||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | $ 13,900 | $ 13,900 | 6,100 | |||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable, current | $ 60,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 18% | 10% | ||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.78 | 1 | $ 1.50 | |||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 70% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 34,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 3,000 | 19,000 | 35,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
Convertible note premium description | The 25% premium will be recorded once a demand occurs | The 25% premium will be recorded once a demand occurs | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt default interest rate | 18% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 16,147 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued | shares | 10,667 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 6,667 | 37,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price increase decrease | $ / shares | $ 0.78 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants or rights outstanding | shares | 73,398 | 73,398 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note April 2021 [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 1.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note April 2021 [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.78 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note April 2021 [Member] | Investor [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 40,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1.90 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note April 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.89 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note April 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 240.64 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - June 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 66,500 | $ 57,000 | $ 57,000 | $ 66,500 | ||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | 10% | ||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Jun. 25, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | $ 421 | 3,400 | 3,000 | 10,400 | 3,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 9,300 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 15,700 | 15,700 | $ 5,700 | |||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable, current | $ 63,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.78 | $ 1.50 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 3 years | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 5,040 | 9,100 | 9,100 | 38,700 | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 15,784 | $ 10,000 | 30,810 | $ 29,600 | 30,810 | |||||||||||||||||||||||||||||||||||||||||||||||
Conversion instrument amount | $ 9,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 12,721 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Loss on extinguishment of debt | $ 18,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Gain on extinguishment of debt | 23,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | $ 63,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 21,436 | 40,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Unamortized debt issuance expense | $ 9,300 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1.90 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 3,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | $ 76,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 2,377 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | $ 102,823 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative expense | 87,039 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 66,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of debt gain loss net of tax | $ 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Trading securities debt | 28,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative fair value of derivative net | $ 23,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - June 2021 [Member] | June 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 0.78 | $ 0.78 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants or rights outstanding | shares | 97,436 | 97,436 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Secured Convertible Promissory Note - August 11, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 220,500 | 220,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 15,800 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 15,800 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 1 | $ 1.50 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 220,500 | 134,100 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 106,505 | 86,400 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 36,000 | 40,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 10,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | $ 210,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 7,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | $ 340,893 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative expense | $ 234,388 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt term | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||
Secured Convertible Promissory Note - August 17, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 220,500 | 220,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Feb. 17, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 15,400 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 15,400 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 1.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 220,500 | 157,900 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 100,571 | 62,600 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 40,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 10,500 | 10,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | $ 210,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | 398,404 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative expense | 297,833 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Secured Convertible Promissory Note - August 17, 2021 [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 1.60 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Secured Convertible Promissory Note Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt term | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - October 4, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 131,250 | $ 131,250 | $ 16,708 | $ 16,708 | 131,250 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 15,000 | $ 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | 10% | 16% | |||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 500 | 5,700 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 32,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 3,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt payment Interest | $ 8,428 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.78 | $ 1.50 | $ 1.50 | |||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 131,250 | $ 131,250 | 1,100 | 1,100 | 99,200 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 77,891 | 33,100 | 98,200 | |||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 2,173 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | 83,500 | 19,471 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 23,810 | 23,810 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Unamortized debt issuance expense | $ 32,109 | $ 32,109 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | 6,250 | 6,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | 110,000 | 110,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | 564,943 | $ 564,943 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative expense | $ 487,052 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible redeemable percentage | 10% | 10% | ||||||||||||||||||||||||||||||||||||||||||||||||||
Aggregate exercise price | $ 45,238 | $ 45,238 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Expense | 3,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | 11,571 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Agreegate exercise price amount | 45,238 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Discount related issuance cost | 15,000 | 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment fee | 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note October 7, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 131,250 | 19,471 | 19,471 | 131,250 | $ 16,708 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 500 | 5,800 | 3,100 | |||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 3,100 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt payment Interest | 476 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | 0.78 | $ 1.50 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 131,250 | $ 131,250 | 2,200 | 2,200 | 100,300 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 76,517 | 33,100 | 98,200 | 30,900 | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | 83,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 23,810 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 6,250 | 6,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | 110,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | 564,184 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative expense | 487,667 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Aggreggate exercise price | 45,238 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 82,900 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Agreegate exercise price amount | 45,238 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Discount related issuance cost | $ 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment fee | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
February 2020 Convertible Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | 457,359 | 457,359 | 98,141 | |||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 70,160 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion instrument amount | $ 554,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 168,301 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 98,141 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest payable | 168,000 | 168,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 386,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
April 2021 Convertible Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for warrants exercise | shares | 7,662 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Cashless exercise of warrants | shares | 12,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note August 11, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | 220,500 | 85,000 | 85,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Sep. 30, 2022 | Aug. 11, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 6,800 | 3,000 | 92,000 | 3,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 43,700 | 43,700 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt payment Interest | $ 64,305 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.78 | $ 1 | $ 1.50 | |||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | 24% | 65% | |||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 106,505 | 39,900 | 30,810 | $ 134,000 | 30,810 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | 128,502 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 36,000 | 40,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 0.78 | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 10,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | 210,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | 340,893 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative expense | $ 234,388 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued or options issued | shares | 21,436 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest payable | 54,278 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 45,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | $ 135,695 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Additional interest | $ 67,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note August 11, 2021 [Member] | August 11,2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 0.78 | $ 0.78 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants or rights outstanding | shares | 97,436 | 97,436 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note August 11, 2021 [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 1.60 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note August 17, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | 220,500 | $ 220,500 | $ 220,500 | |||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Aug. 17, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 12,700 | 2,700 | 37,700 | 2,700 | ||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 53,100 | 53,100 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.78 | $ 1.50 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | 65% | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 52,800 | 52,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 100,571 | $ 35,400 | 27,200 | $ 105,000 | 27,200 | |||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 40,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 0.78 | $ 1.60 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 10,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | 210,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | 398,404 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative expense | $ 297,833 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued or options issued | shares | 21,436 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt and warrant exercise price per share | $ / shares | $ 0.78 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note August 17, 2021 [Member] | August 17 2022 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 0.78 | $ 0.78 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants or rights outstanding | shares | 97,436 | 97,436 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note August 17, 2021 [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 1.60 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Senior secured convertible promissory note Seven [Member] | October 4 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1.90 | $ 1.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants or rights outstanding | shares | 23,810 | 23,810 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Senior secured convertible promissory note eight [Member] | October 7 2022 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1.90 | $ 1.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants or rights outstanding | shares | 23,810 | 23,810 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - March 15, 2022 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 250,000 | $ 182,800 | $ 182,800 | |||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 13,600 | 13,600 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt payment Interest | 11,396 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 113,000 | 113,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 250,000 | 63,000 | 137,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | 39,285.71 | 67,176 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 180,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of Debt Issuance Costs | 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 42,600 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Discount related issuance cost | 34,384 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Guaranteed interest contracts | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - March 15, 2022 [Member] | Investor [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 2,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 66,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 32,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.45 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 240.83 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note April 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 1.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 11 months 15 days | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,700 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ 11,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued | shares | 10,667 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note April 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.92 | 0.89 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note April 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 247.52 | 240.64 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 5,800 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 6 months 25 days | 7 months 6 days | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 37,916 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 15,784 | 27,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 25,333 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued | shares | 10,667 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1 | $ 1.50 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Additional warrants issued | shares | 25,333 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.81 | 0.48 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 209 | 302.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 56,454 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Unamortized debt issuance expense | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1.90 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.81 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 253 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 62,220 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Unamortized debt issuance expense | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1.90 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.77 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 24% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 254 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Secured Convertible Promissory Note Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 1,314,000 | 377,269 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Loss on fair value of derivative liabilities | 1,534 | 4,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | 1,422,000 | 1,422,000 | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
Derivative expense | 108,000 | 1,593,978 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note - October 4, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 15,000 | 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Unamortized debt issuance expense | $ 32,109 | $ 32,109 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1.90 | $ 1.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note October 7, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1.90 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note August 11, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 56,454 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1.90 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note August 11, 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.0081 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note August 11, 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 2.53 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note August 17, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 62,220 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1.90 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note August 17, 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 24% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.0077 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note August 17, 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 2.54 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | 1,000 | 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Senior Secured Convertible Promissory Note April 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | $ 19,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1.60 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 17,041 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 17,209 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 5,631 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Convertible Promissory Note - October 4, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 77,891 | $ 77,891 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 2,977 | 476 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | $ 81,700 | $ 14,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Convertible Promissory Note October 7, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 33,483 | $ 33,483 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 2,977 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 15,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Convertible Promissory Note August 11, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 17,041 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 7,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Convertible Promissory Note August 17, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 17,209 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 5,631 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Convertible Promissory Note - March 15, 2022 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 3,596 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Eight Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | 1,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 1 | $ 0.78 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion instrument amount | $ 554,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 168,294 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | $ 168,300 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Loss on extinguishment of debt | 386,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Loss on fair value of derivative liabilities | 245,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Gain on extinguishment of debt | 245,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | 141,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of debt gain loss net of tax | 141,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Senior Secured Convertible Promissory Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 14,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 18% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 11,000 | 5,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 70,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.78 | $ 0.40 | $ 0.78 | |||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | 65% | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt default interest rate | 18% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible, beneficial conversion feature | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Beneficial conversion feature | 203,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 16,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Secured Convertible Promissory Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 58,055 | $ 58,055 | $ 58,055 | |||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 140% | 140% | 140% | |||||||||||||||||||||||||||||||||||||||||||||||||
Convertible note premium description | The 40% premium will be recorded once a demand occurs. | The 40% premium will be recorded once a demand occurs | ||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 23,500 | $ 23,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Senior Secured Convertible Promissory Note One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 4,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.78 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 106,505 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 1 | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 100,571 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 36,000 | 36,000 | 36,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1 | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Convertible Promissory Note October 7, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt payment Interest | 8,428 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 76,517 | $ 76,517 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | $ 11,571 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Convertible Promissory Note August 11, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 106,505 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Convertible Promissory Note August 17, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 100,571 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Convertible Promissory Note - March 15, 2022 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 162,020 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | $ / shares | $ 0.78 | $ 0.78 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants or rights outstanding | shares | 162,800 | 162,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note [Member] | Senior Secured Convertible Promissory Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | 58,055 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 14,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Dec. 26, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.40 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 5,555 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | 52,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible, beneficial conversion feature | 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Beneficial conversion feature | $ 203,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Ten Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 1,100,000 | $ 1,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Registration Rights Agreement [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Registration Rights Agreement [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Registration Rights Agreement [Member] | Convertible Promissory Note - October 4, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 2,977 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Registration Rights Agreement [Member] | Convertible Promissory Note October 7, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 2,977 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued or options issued | shares | 2,632 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Registration Rights Agreement [Member] | Convertible Promissory Note August 11, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Registration Rights Agreement [Member] | Convertible Promissory Note August 17, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Term Loan Subscription Agreements [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 5,700,000 | $ 5,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 707,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 12% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest during period | 15% | 15% | ||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Jun. 28, 2020 | Jun. 28, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 212,000 | 215,000 | $ 637,000 | 637,000 | $ 852,000 | 1,200,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 347,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | $ 2,700,000 | 2,700,000 | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | 5,700,000 | 5,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt payment Interest | $ 2,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Securities purchase agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 550,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | 18% | ||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Aug. 05, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable, current | $ 499,950 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Weighted average percentage | 70% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 60% | 60% | ||||||||||||||||||||||||||||||||||||||||||||||||||
Stock combinations | $ / shares | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 381,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.78 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Securities purchase agreement [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 322,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Securities purchase agreement [Member] | Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 96,000 | 75,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 38,000 | 38,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 21,000 | $ 381,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Securities purchase agreement [Member] | Convertible Debt [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 53,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Securities purchase agreement [Member] | Convertible Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | 457,359 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 140% | 140% | ||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | $ 101,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion instrument amount | $ 31,150 | $ 26,250 | $ 32,500 | $ 25,000 | $ 27,500 | $ 25,900 | ||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 31,151 | 26,250 | 32,500 | 25,000 | 27,500 | 25,900 | ||||||||||||||||||||||||||||||||||||||||||||||
Convertible note premium description | The 40% premium will be recorded once a demand occurs | The 40% premium will be recorded once a demand occurs. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Holders [Member] | Securities purchase agreement [Member] | Convertible Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 140% | |||||||||||||||||||||||||||||||||||||||||||||||||||
Investors [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 1,151,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Investors [Member] | Securities purchase agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | 2,222,222 | $ 2,222,222 | $ 2,222,222 | |||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 45,400 | 70,600 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 307,800 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 70,600 | 70,600 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 66 months | |||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 1,693,000 | 1,029,000 | 1,029,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 562,300 | $ 0 | $ 663,300 | $ 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | $ 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 1,111,112 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 222,222 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 19,231 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 1,692,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of Debt Issuance Costs | $ 307,800 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants maturity date | Nov. 11, 2027 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price increase decrease | $ / shares | $ 0.80 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Investors [Member] | Securities purchase agreement [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 11,820 |
Licensing Agreements (Details N
Licensing Agreements (Details Narrative) - USD ($) | 1 Months Ended | 12 Months Ended | ||||
Dec. 23, 2019 | Mar. 16, 2018 | May 31, 2018 | Dec. 31, 2021 | Dec. 31, 2020 | Jun. 30, 2020 | |
Other income | $ 45,000 | |||||
Novosom Verwaltungs Gmb H [Member] | Intellectual Property [Member] | ||||||
Stock Issued During Period, Shares, Purchase of Assets | 2,599 | |||||
Stock Issued During Period, Value, Purchase of Assets | $ 75,000 | |||||
Acquired intellectual property | $ 45,000 | |||||
Novosom Verwaltungs Gmb H [Member] | Intellectual Property [Member] | Upon Execution Of Agreement [Member] | ||||||
Acquired intellectual property, paid | $ 20,000 | |||||
Novosom Verwaltungs Gmb H [Member] | Intellectual Property [Member] | Achievement Of Performance Obligation [Member] | ||||||
Acquired intellectual property, paid | $ 25,000 | |||||
Les Laboratories Servier License Agreement [Member] | ||||||
Payments for royalties | 0 | 0 | ||||
Novosom Agreement [Member] | ||||||
Other income | $ 45,000 | |||||
Revenues | $ 0 | |||||
License Of Di L A Assets [Member] | Accrued Liabilities [Member] | ||||||
Upfront payment agreement for license agreement | $ 200,000 | |||||
Sub-Licensing Agreement [Member] | Accrued Liabilities [Member] | ||||||
Upfront payment agreement for license agreement | $ 200,000 |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||
Due to Related Parties | $ 4,000 | $ 4,000 | |
Officers And Directors [Member] | |||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||
Due from related parties | $ 1,000 | $ 42,000 |
Schedule of Stockholders_ Equit
Schedule of Stockholders’ Equity Note, Warrants or Rights (Details) - shares | Sep. 30, 2022 | Dec. 31, 2021 |
EquityLineItems [Line Items] | ||
Warrant shares | 5,192,652 | 3,731,263 |
Expiring in 2023 | 1,674,718 | 1,675,209 |
Expiring in 2024 | 3,236,550 | 140,395 |
Expiring in 2025 | 1,899,917 | 1,646,092 |
Expiring in 2026 | 345,600 | 269,567 |
Expiring in 2027 | 1,111,112 | |
Convertible Notes [Member] | ||
EquityLineItems [Line Items] | ||
Warrant shares | 2,389,394 | 2,039,117 |
Expiring in 2023 | ||
Expiring in 2024 | 145,056 | 123,620 |
Expiring in 2025 | 36,777,552 | 1,645,930 |
Expiring in 2026 | 345,600 | 269,567 |
Other [Member] | ||
EquityLineItems [Line Items] | ||
Warrant shares | 17,441 | 17,441 |
Expiring in 2023 | 13 | 504 |
Expiring in 2024 | 1,179 | 16,775 |
Expiring in 2025 | 3,201 | 162 |
Expiring in 2026 | ||
Bridge Loan [Member] | ||
EquityLineItems [Line Items] | ||
Warrant shares | 1,111,112 | |
Expiring in 2027 | 1,111,112 | |
Series E Preferred Stock [Member] | ||
EquityLineItems [Line Items] | ||
Warrant shares | 1,520,280 | 1,520,280 |
Expiring in 2023 | 1,520,280 | 1,520,280 |
Expiring in 2024 | ||
Expiring in 2025 | ||
Expiring in 2026 | ||
Series F Preferred Stock [Member] | ||
EquityLineItems [Line Items] | ||
Warrant shares | 154,425 | 154,425 |
Expiring in 2023 | 154,425 | 154,425 |
Expiring in 2024 | ||
Expiring in 2025 | ||
Expiring in 2026 |
Stockholders_ Equity (Details N
Stockholders’ Equity (Details Narrative) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||
May 17, 2022 USD ($) $ / shares shares | May 12, 2022 USD ($) shares | May 11, 2022 USD ($) shares | Mar. 15, 2022 USD ($) shares | Jan. 27, 2022 USD ($) $ / shares shares | Dec. 06, 2021 USD ($) shares | Nov. 23, 2021 USD ($) shares | Nov. 04, 2021 shares | Nov. 04, 2021 USD ($) shares | Oct. 15, 2021 USD ($) shares | Oct. 12, 2021 USD ($) shares | Oct. 12, 2021 USD ($) shares | Oct. 08, 2021 USD ($) shares | Oct. 05, 2021 USD ($) shares | Oct. 04, 2021 USD ($) shares | Oct. 04, 2021 USD ($) shares | Sep. 22, 2021 USD ($) shares | Aug. 18, 2021 USD ($) shares | Aug. 11, 2021 USD ($) shares | Jul. 30, 2021 USD ($) shares | Jun. 27, 2021 USD ($) | Jun. 08, 2021 USD ($) shares | Mar. 19, 2021 USD ($) $ / shares shares | Dec. 21, 2020 USD ($) shares | Dec. 11, 2020 USD ($) shares | Oct. 30, 2019 USD ($) shares | Sep. 30, 2022 USD ($) $ / shares shares | Jun. 30, 2022 USD ($) shares | Mar. 31, 2022 USD ($) shares | Sep. 30, 2021 USD ($) shares | Mar. 31, 2021 USD ($) shares | Sep. 30, 2022 USD ($) $ / shares shares | Sep. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) $ / shares shares | Dec. 31, 2020 USD ($) $ / shares shares | Jan. 31, 2022 $ / shares | Nov. 30, 2021 $ / shares shares | Jun. 25, 2021 $ / shares | Jun. 26, 2020 $ / shares | Dec. 31, 2019 shares | Aug. 05, 2019 USD ($) | Jul. 31, 2018 shares | Apr. 30, 2018 shares | Aug. 31, 2015 shares | Mar. 31, 2014 shares | |
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares authorized | 100,000 | 100,000 | 100,000 | 100,000 | |||||||||||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||
Weighted average exercise price | $ / shares | $ 0.88 | $ 0.88 | $ 1 | $ 1 | $ 1.60 | ||||||||||||||||||||||||||||||||||||||||
Warrant, shares | 12,500 | 12,500 | 5,192,652 | 5,192,652 | 3,731,263 | 19,084 | |||||||||||||||||||||||||||||||||||||||
Stock Repurchased During Period, Value | $ | $ 2,000 | ||||||||||||||||||||||||||||||||||||||||||||
Debt conversion | $ | $ 554,000 | ||||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | 5,192,652 | 5,192,652 | 3,731,263 | ||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 133,284 | ||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ | $ 11,000 | $ 28,000 | $ 85,000 | $ 26,000 | $ 554,000 | ||||||||||||||||||||||||||||||||||||||||
Loss on extinguishment of debt | $ | 386,000 | ||||||||||||||||||||||||||||||||||||||||||||
Intrinsic value | $ | $ 2,500,000 | $ 2,500,000 | $ 1,492,503 | ||||||||||||||||||||||||||||||||||||||||||
Conversion rate per share | $ / shares | $ 0.006 | $ 0.006 | $ 0.006 | $ 0.006 | |||||||||||||||||||||||||||||||||||||||||
Shares issued for warrants exercise | 7,662 | ||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of debt | $ | $ 92,000 | $ (177,000) | $ 307,000 | $ (177,000) | $ (141,000) | ||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Debt conversion | $ | $ 554,000 | ||||||||||||||||||||||||||||||||||||||||||||
Common shares issued | 168,294 | ||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ | $ 141,000 | ||||||||||||||||||||||||||||||||||||||||||||
Loss on extinguishment of debt | $ | 386,000 | ||||||||||||||||||||||||||||||||||||||||||||
Gain on extinguishment of debt | $ | 245,000 | ||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Gain (Loss), Net of Tax | $ | 141,000 | ||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.78 | $ 1 | |||||||||||||||||||||||||||||||||||||||||||
February 2020 Convertible Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Debt conversion | $ | $ 554,000 | ||||||||||||||||||||||||||||||||||||||||||||
Common shares issued | 168,301 | ||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 168,294 | ||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ | $ 98,141 | ||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ | 70,160 | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ | 457,359 | 457,359 | 98,141 | ||||||||||||||||||||||||||||||||||||||||||
Extinguishment of debt | $ | $ 386,000 | ||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Warrant issued, shares | 12,500 | ||||||||||||||||||||||||||||||||||||||||||||
April 2021 Convertible Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Cashless exercise of warrants | 250,000 | ||||||||||||||||||||||||||||||||||||||||||||
Shares issued for warrants exercise | 7,662 | ||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ | $ 2,700 | $ 7,900 | $ 17,000 | ||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ | $ 5,700,000 | ||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ | $ 11,000 | $ 5,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.78 | $ 0.78 | $ 0.40 | ||||||||||||||||||||||||||||||||||||||||||
Banking Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 19,231 | 10,000 | 4,805 | 15,008 | |||||||||||||||||||||||||||||||||||||||||
Fair value | $ | $ 11,820 | $ 14,384 | $ 18,745 | $ 39,290 | |||||||||||||||||||||||||||||||||||||||||
Convertible Note Investor [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 2,500 | 12,721 | 2,977 | 2,977 | 2,977 | 5,000 | 5,000 | ||||||||||||||||||||||||||||||||||||||
Fair value | $ | $ 3,596 | $ 12,233 | $ 10,859 | $ 10,859 | $ 62,220 | $ 56,464 | |||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ | $ 9,500 | ||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ | 422 | ||||||||||||||||||||||||||||||||||||||||||||
Loss on extinguishment of debt | $ | 18,000 | ||||||||||||||||||||||||||||||||||||||||||||
Debt Securities, Trading | $ | 28,000 | ||||||||||||||||||||||||||||||||||||||||||||
Derivative, Fair Value, Net | $ | 23,000 | ||||||||||||||||||||||||||||||||||||||||||||
Gain on extinguishment of debt | $ | $ 23,000 | ||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Gain (Loss), Net of Tax | $ | $ 5,000 | ||||||||||||||||||||||||||||||||||||||||||||
Series E Preferred [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 12,777 | ||||||||||||||||||||||||||||||||||||||||||||
Series F Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | 154,425 | 154,425 | 154,425 | ||||||||||||||||||||||||||||||||||||||||||
Series E Warrants [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Weighted average exercise price | $ / shares | $ 0.78 | ||||||||||||||||||||||||||||||||||||||||||||
Conversion of stock, amount converted | $ | $ 25,900 | ||||||||||||||||||||||||||||||||||||||||||||
Conversion of shares | 25,900 | ||||||||||||||||||||||||||||||||||||||||||||
Debt conversion | $ | $ 25,900 | ||||||||||||||||||||||||||||||||||||||||||||
Common shares issued | 25,900 | ||||||||||||||||||||||||||||||||||||||||||||
Warrant issued, shares | 3,750 | ||||||||||||||||||||||||||||||||||||||||||||
Series E Warrants [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Weighted average exercise price | $ / shares | $ 10 | ||||||||||||||||||||||||||||||||||||||||||||
Series E Warrants [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Weighted average exercise price | $ / shares | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||
Series E Preferred [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Conversion of stock, amount converted | $ | $ 250,000 | ||||||||||||||||||||||||||||||||||||||||||||
Conversion of shares | 3,059 | 15 | 5 | 5 | 4 | 30 | 20 | 50 | 8 | ||||||||||||||||||||||||||||||||||||
Accrued dividends | $ | $ 10,000 | ||||||||||||||||||||||||||||||||||||||||||||
Accrued dividends shares | 2,035,306 | 5,051 | |||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 9,665 | 3,216 | 3,216 | 2,571 | 19,271 | 12,777 | 25,000 | 2,679 | |||||||||||||||||||||||||||||||||||||
Cashless exercise of warrants | 3,750 | ||||||||||||||||||||||||||||||||||||||||||||
Fair value | $ | $ 21,649 | $ 7,156 | $ 7,156 | $ 5,707 | $ 42,707 | $ 27,770 | |||||||||||||||||||||||||||||||||||||||
Accrued dividends | $ | $ 5,100,000 | $ 10,000 | |||||||||||||||||||||||||||||||||||||||||||
Conversion rate per share | $ / shares | $ 10 | ||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Conversion of shares | 25,000 | ||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 25,000 | ||||||||||||||||||||||||||||||||||||||||||||
Stock repurchased during period, shares | 5,954 | ||||||||||||||||||||||||||||||||||||||||||||
Stock Repurchased During Period, Value | $ | |||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 19,231 | 12,721 | 85,000 | 25,900 | 168,294 | ||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ | $ 1,000 | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||
Series F Warrants [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Debt conversion | $ | $ 25,900 | ||||||||||||||||||||||||||||||||||||||||||||
Common shares issued | 25,900 | ||||||||||||||||||||||||||||||||||||||||||||
Series F Warrants [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Weighted average exercise price | $ / shares | $ 0.78 | $ 10 | |||||||||||||||||||||||||||||||||||||||||||
Series F Warrants [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Weighted average exercise price | $ / shares | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||
Series F Preferred [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Conversion of shares | 358 | 3 | |||||||||||||||||||||||||||||||||||||||||||
Accrued dividends shares | 233,127 | ||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 1,853 | ||||||||||||||||||||||||||||||||||||||||||||
Fair value | $ | $ 3,521 | ||||||||||||||||||||||||||||||||||||||||||||
Accrued dividends | $ | $ 541,000 | ||||||||||||||||||||||||||||||||||||||||||||
Conversion rate per share | $ / shares | $ 10 | ||||||||||||||||||||||||||||||||||||||||||||
Series E Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Conversion of shares | 10 | 10 | |||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 6,074 | 6,085 | |||||||||||||||||||||||||||||||||||||||||||
Fair value | $ | $ 60,740 | $ 60,850 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Adjustable warrants | 5,127,591 | 5,127,591 | 3,713,822 | ||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations | 17,188 | ||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Note Investor [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 7,662 | ||||||||||||||||||||||||||||||||||||||||||||
Fair value | $ | $ 12,500 | ||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Note Investor [Member] | Banking Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 4,805 | ||||||||||||||||||||||||||||||||||||||||||||
Fair value | $ | $ 18,745 | ||||||||||||||||||||||||||||||||||||||||||||
Preferred and accrued dividends [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Accrued dividends | $ | $ 5,100,000 | ||||||||||||||||||||||||||||||||||||||||||||
Series E preferred and accrued dividends [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Accrued dividends shares | 2,035,306 | ||||||||||||||||||||||||||||||||||||||||||||
Preferred and accrued dividend [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Accrued dividends | $ | $ 541,000 | ||||||||||||||||||||||||||||||||||||||||||||
Series F preferred and accrued dividend [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Accrued dividends shares | 233,127 | ||||||||||||||||||||||||||||||||||||||||||||
Treasury Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Stock repurchased during period, shares | 5,954 | ||||||||||||||||||||||||||||||||||||||||||||
Stock Repurchased During Period, Value | $ | 2,000 | ||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ | |||||||||||||||||||||||||||||||||||||||||||||
Commitment fee | $ | $ 2,000 | ||||||||||||||||||||||||||||||||||||||||||||
Series B Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Preferred stock designated shares | 1,000 | 1,000 | 1,000 | ||||||||||||||||||||||||||||||||||||||||||
Series A Junior Participating Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Preferred stock designated shares | 90,000 | 90,000 | 90,000 | ||||||||||||||||||||||||||||||||||||||||||
Series A Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||
Series C Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares authorized | 1,200 | 1,200 | 1,200 | 1,200 | |||||||||||||||||||||||||||||||||||||||||
Preferred stock designated shares | 1,200 | ||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 100 | 100 | 100 | 100 | |||||||||||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||
Preferred stock shares issued | 100 | 100 | 100 | 100 | |||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Liquidation Preference, Value | $ | $ 510,000,000 | $ 510,000,000 | $ 510,000,000 | $ 510,000,000 | |||||||||||||||||||||||||||||||||||||||||
Series D Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares authorized | 220 | 220 | 220 | 220 | |||||||||||||||||||||||||||||||||||||||||
Preferred stock designated shares | 220 | ||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 40 | 40 | 40 | 40 | |||||||||||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||
Preferred stock shares issued | 40 | 40 | 40 | 40 | |||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Liquidation Preference, Value | $ | $ 12,000,000 | $ 12,000,000 | $ 12,000,000 | $ 12,000,000 | |||||||||||||||||||||||||||||||||||||||||
Series E Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares authorized | 3,500 | 3,500 | 3,500 | 3,500 | |||||||||||||||||||||||||||||||||||||||||
Preferred stock designated shares | 3,500 | ||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 267 | 267 | 3,326 | 3,458 | |||||||||||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||
Preferred stock shares issued | 267 | 267 | 3,326 | 3,458 | |||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Liquidation Preference, Value | $ | $ 1,788,319,000 | $ 1,788,319,000 | $ 21,618,999,000 | $ 21,618,999,000 | |||||||||||||||||||||||||||||||||||||||||
Series F Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares authorized | 2,200 | 2,200 | 2,200 | 2,200 | |||||||||||||||||||||||||||||||||||||||||
Preferred stock designated shares | 2,200 | ||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 0 | 0 | 358 | 361 | |||||||||||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||
Conversion of shares | 358 | ||||||||||||||||||||||||||||||||||||||||||||
Warrant, shares | 7,500 | ||||||||||||||||||||||||||||||||||||||||||||
Stock repurchased during period, shares | 20 | ||||||||||||||||||||||||||||||||||||||||||||
Stock Repurchased During Period, Value | $ | $ 100,000 | ||||||||||||||||||||||||||||||||||||||||||||
Value of warrants held | $ | $ 100,000 | ||||||||||||||||||||||||||||||||||||||||||||
Accrued dividends | $ | $ 488,000 | $ 347,000 | |||||||||||||||||||||||||||||||||||||||||||
Preferred stock shares issued | 0 | 0 | 358 | 361 | |||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Liquidation Preference, Value | $ | $ 2,277,509,000 | $ 2,277,509,000 | |||||||||||||||||||||||||||||||||||||||||||
Accrued dividends | $ | $ 0 | $ 0 | $ 448,000 | ||||||||||||||||||||||||||||||||||||||||||
Series G Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares authorized | 6,000 | 6,000 | 6,000 | 6,000 | |||||||||||||||||||||||||||||||||||||||||
Preferred stock designated shares | 6,000 | ||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||
Preferred stock shares issued | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Liquidation Preference, Value | $ | $ 5,000,000 | $ 5,000,000 | $ 5,000,000 | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||
Series C Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 100 | 100 | 100 | 100 | |||||||||||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 5,000 | $ 5,000 | $ 5,000 | ||||||||||||||||||||||||||||||||||||||||||
Preferred stock liquidation preference per share | $ / shares | $ 5,100 | ||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Voting Rights | voting rights of 33.33 votes per share | voting rights of 33.33 votes per Series C Preferred share | |||||||||||||||||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ / shares | $ 150 | ||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Liquidation Preference, Value | $ | $ 5,100 | $ 5,100 | |||||||||||||||||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ / shares | $ 150 | $ 150 | |||||||||||||||||||||||||||||||||||||||||||
Series D Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 40 | 40 | 40 | 40 | |||||||||||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 5,000 | $ 5,000 | $ 5,000 | ||||||||||||||||||||||||||||||||||||||||||
Preferred stock liquidation preference per share | $ / shares | $ 300 | ||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Voting Rights | voting rights of 62.5 votes per share | voting rights of 62.5 votes per Series D Preferred share | |||||||||||||||||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ / shares | $ 80 | ||||||||||||||||||||||||||||||||||||||||||||
Preferred stock stated dividend rate | 5% | 5% | |||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Liquidation Preference, Value | $ | $ 300 | $ 300 | |||||||||||||||||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ / shares | $ 80 | $ 80 | |||||||||||||||||||||||||||||||||||||||||||
Series E Convertible Preferred Stock and Warrants [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | 5,000 | $ 5,000 | $ 5,000 | ||||||||||||||||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ / shares | $ 10 | ||||||||||||||||||||||||||||||||||||||||||||
Preferred stock stated dividend rate | 8% | 8% | |||||||||||||||||||||||||||||||||||||||||||
Antidilution price protection | Feb. 10, 2020 | Feb. 10, 2020 | |||||||||||||||||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ / shares | $ 10 | $ 10 | |||||||||||||||||||||||||||||||||||||||||||
Series E Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 267 | 267 | 3,326 | 3,458 | |||||||||||||||||||||||||||||||||||||||||
Weighted average exercise price | $ / shares | $ 0.78 | $ 0.78 | $ 1 | ||||||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ | $ 390,000 | ||||||||||||||||||||||||||||||||||||||||||||
Warrant, shares | 1,453,028 | 1,453,028 | 1,520,280 | ||||||||||||||||||||||||||||||||||||||||||
Accrued dividends | $ | $ 5,000,000 | $ 3,700,000 | |||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | 1,520,280 | 1,520,280 | 1,520,280 | ||||||||||||||||||||||||||||||||||||||||||
Accrued dividends | $ | $ 453,000 | $ 453,000 | $ 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||
Series E Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Fair value of warrants measurement inputs | 0.16 | ||||||||||||||||||||||||||||||||||||||||||||
Series E Preferred Stock [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Fair value of warrants measurement inputs | 262.27 | ||||||||||||||||||||||||||||||||||||||||||||
Series E Preferred Stock [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 5 months 4 days | ||||||||||||||||||||||||||||||||||||||||||||
Series E Preferred Stock [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 4 months 28 days | ||||||||||||||||||||||||||||||||||||||||||||
Series F Convertible Preferred Stock and Warrants [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 5,000 | $ 5,000 | $ 5,000 | ||||||||||||||||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ / shares | $ 10 | ||||||||||||||||||||||||||||||||||||||||||||
Preferred stock stated dividend rate | 8% | 8% | |||||||||||||||||||||||||||||||||||||||||||
Antidilution price protection | Feb. 10, 2020 | Feb. 10, 2020 | |||||||||||||||||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ / shares | $ 10 | $ 10 | |||||||||||||||||||||||||||||||||||||||||||
Series F Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 358 | 361 | |||||||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ | $ 31,000 | ||||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | 154,425 | 154,425 | 154,425 | ||||||||||||||||||||||||||||||||||||||||||
Series F Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Fair value of warrants measurement inputs | 0.16 | ||||||||||||||||||||||||||||||||||||||||||||
Series F Preferred Stock [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Fair value of warrants measurement inputs | 262.27 | ||||||||||||||||||||||||||||||||||||||||||||
Series F Preferred Stock [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 6 months 10 days | ||||||||||||||||||||||||||||||||||||||||||||
Series F Preferred Stock [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 5 months 15 days | ||||||||||||||||||||||||||||||||||||||||||||
Series G Convertible Preferred Shares [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 5,000 | $ 5,000 | $ 5,000 | ||||||||||||||||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ / shares | $ 10 | ||||||||||||||||||||||||||||||||||||||||||||
Preferred stock stated dividend rate | 8% | 8% | |||||||||||||||||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ / shares | $ 10 | $ 10 | |||||||||||||||||||||||||||||||||||||||||||
Series G Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||
EquityLineItems [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
Preferred stock shares issued | 0 | 0 | 0 |
Schedule of Share Based Payment
Schedule of Share Based Payments Arrangement, Option Activity (Details) - $ / shares | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-Based Payment Arrangement [Abstract] | |||
Options Outstanding Beginning | 19,203 | 19,568 | 203,568 |
Options outstanding, weighted average exercise price, beginning | $ 19.40 | $ 20 | $ 11.60 |
Options expired / forfeited | (203) | (365) | (184,000) |
Options expired/forfeited, weighted average exercise price | $ 34 | $ 36.60 | $ 10.60 |
Options Outstanding Ending | 19,000 | 19,203 | 19,568 |
Options outstanding, weighted average exercise price, ending | $ 19.60 | $ 19.40 | $ 20 |
Options Exercisable | 19,000 | 19.203 | |
Exercisable, weighted average exercise price | $ 19.60 | $ 19.40 | |
Options Outstanding Ending | 19,000 | 19,203 | 19,568 |
Options outstanding, weighted average exercise price, ending | $ 19.60 | $ 19.40 | $ 20 |
Schedule of Share Based Payme_2
Schedule of Share Based Payment Arrangement, Option, Exercise Price Range (Details) - $ / shares | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Number outstanding | 19,000 | 19,203 |
Weighted- Average Remaining Contractual Life (Years) | 7 months 2 days | 1 year 3 months 25 days |
Weighted average exercise price | $ 19.60 | $ 19.75 |
Number exercisable | 19,000 | 19,203 |
Weighted average exercise price | $ 19.60 | $ 19.75 |
Range One [Member] | ||
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Range of exercise prices | $ 19.60 | $ 19.60 |
Number outstanding | 19,000 | 19,000 |
Weighted- Average Remaining Contractual Life (Years) | 7 months 2 days | 1 year 3 months 29 days |
Weighted average exercise price | $ 19.60 | $ 19.60 |
Number exercisable | 19,000 | 19,000 |
Weighted average exercise price | $ 19.60 | $ 19.60 |
Range Two [Member] | ||
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||
Number outstanding | 203 | |
Weighted- Average Remaining Contractual Life (Years) | 7 days | |
Weighted average exercise price | $ 34 | |
Number exercisable | 203 | |
Weighted average exercise price | $ 34 | |
Range of exercise prices, upper | $ 34 |
Stock Incentive Plans (Details
Stock Incentive Plans (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Shares granted | 0 | |||||
unvested options | $ 0 | $ 0 | ||||
Stock based compensation expenses | $ 0 | $ 0 | $ 0 | $ 0 | $ 8,000 | |
Share-Based Payment Arrangement, Option [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Share-based Payment Arrangement, Expense | $ 0 | $ 8,000 | ||||
Share based compensation options outstanding exercisable | $ 1.40 |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | |||||||||
Jul. 20, 2022 | Aug. 24, 2021 | Jul. 28, 2021 | Oct. 30, 2019 | Feb. 16, 2022 | Nov. 17, 2021 | Jun. 30, 2022 | Sep. 30, 2022 | Dec. 31, 2021 | Nov. 30, 2021 | Nov. 04, 2021 | |
Loss Contingencies [Line Items] | |||||||||||
Warrants to purchase shares of common stock | 5,192,652 | 3,731,263 | 19,084 | 12,500 | |||||||
Stock repurchase | $ 2,000 | ||||||||||
Melior Pharmaceuticals [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
License agreement commitments description | the Company’s timeline from 120 days to 180 days from the effective of the agreement for the Company to raise $4.0 million dollars unless, by 180 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising | ||||||||||
Licensing Agreement MLR1019 [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Debt Instrument, Periodic Payment | $ 21,800,000 | ||||||||||
Gross sales percentage | 5% | ||||||||||
Option purchase percentage | 10% | ||||||||||
Royalty gross sales percentage | 2.50% | ||||||||||
Licensing Agreement MLR1019 [Member] | Minimum [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Gross sales percentage | 8% | ||||||||||
Licensing Agreement MLR1019 [Member] | Maximum [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Gross sales percentage | 12% | ||||||||||
Licensing Agreement MLR1023 [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Debt Instrument, Periodic Payment | $ 21,800,000 | ||||||||||
License agreement commitments description | if the Company failed to raise $4.0 million dollars within 120 days of the Effective Date of the agreement then the License would immediately terminate unless, by 120 Days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 Days would be provided to allow for the completion of the raise | the Company and Melior I, extending the requirement by the Company to raise $4.0 million dollars to June 16, 2022 | the Company’s timeline from 120 days to 180 days from the effective of the agreement for the Company to raise $4.0 million dollars unless, by 180 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising | ||||||||
Licensing Agreement MLR1023 [Member] | Melior Pharmaceuticals One Inc [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
License agreement commitments description | if the Company failed to raise $4.0 million dollars within 120 days of the Effective Date then the License would immediately terminate unless, by 120 Days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 Days would be provided to allow for the completion of the raise | ||||||||||
Licensing agreement [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Payment for licensing agreement | $ 136,921 | ||||||||||
Licensing agreement [Member] | Chief Scientific Officer [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Capital raise in additional | $ 500,000 | ||||||||||
Series F Convertible Preferred Stock [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Number of shares repurchased | 20 | ||||||||||
Warrants to purchase shares of common stock | 7,500 | ||||||||||
Stock repurchase | $ 100,000 | ||||||||||
Value of warrants held | $ 100,000 |
Schedule of Deferred Tax Assets
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Income Tax Disclosure [Abstract] | ||
Net operating loss carryforwards | $ 8,402 | $ 7,741 |
Inventory reserve | 114 | |
Depreciation and amortization | 1,272 | 2,226 |
Share based compensation | 647 | 599 |
Other | 613 | 297 |
Total deferred tax assets | 10,935 | 10,977 |
Valuation allowance | (10,935) | (10,977) |
Net deferred tax assets | ||
Deferred tax liabilities: | ||
Intangible assets | ||
Net deferred tax liabilities |
Income Taxes (Details Narrative
Income Taxes (Details Narrative) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | ||
Net operating loss carry-forwards | $ 326 | |
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | $ 42,000 | $ 0.6 |
Schedule of Outstanding Term Lo
Schedule of Outstanding Term Loans (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Short-Term Debt [Line Items] | ||
Notes payable | $ 7,899 | $ 5,677 |
Unamortized discounts | (1,029) | |
Loans payable | 6,870 | 5,677 |
2019 Term Loan [Member] | ||
Short-Term Debt [Line Items] | ||
Notes payable | 5,677 | 5,677 |
2022 Term Loan [Member] | ||
Short-Term Debt [Line Items] | ||
Notes payable | $ 2,222 |
Schedule of Warrants (Details)
Schedule of Warrants (Details) | 9 Months Ended |
Sep. 30, 2022 shares | |
Equity [Abstract] | |
Warrants, Beginning Balance | 3,731,263 |
Issued as a result of price adjustments on CVN | 133,284 |
Variable quantity of warrants related to February 2020 note | 216,993 |
Warrants issued with 2022 Bridge Note | 1,111,112 |
Warrants, Ending Balance | 5,192,652 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) - USD ($) | 9 Months Ended | 12 Months Ended | |||||||||||||||
Oct. 05, 2022 | Mar. 15, 2022 | Feb. 16, 2022 | Jan. 27, 2022 | Jul. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Oct. 15, 2022 | Oct. 07, 2022 | Oct. 04, 2022 | Jan. 31, 2022 | Jan. 05, 2022 | Jan. 02, 2022 | Nov. 30, 2021 | Nov. 09, 2021 | |
Subsequent Event [Line Items] | |||||||||||||||||
Debt conversion, converted instrument, amount | $ 554,000 | ||||||||||||||||
Debt instrument, convertible, conversion price | $ 1 | ||||||||||||||||
Payments of Debt Issuance Costs | $ 328,000 | $ 72,000 | 101,000 | $ 114,000 | |||||||||||||
Interest rate, stated percentage | 24% | ||||||||||||||||
Amendment Certificate Incorporation [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Reverse stock split | ratio of 1-for-20 | ||||||||||||||||
Common Stock [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Stock Issued During Period, Shares, New Issues | 25,000 | ||||||||||||||||
Convertible Debt [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Debt conversion, converted instrument, amount | $ 554,000 | ||||||||||||||||
Debt instrument, convertible, conversion price | $ 0.78 | $ 1 | |||||||||||||||
Debt interest amount, conversion of common stock, shares | 168,294 | ||||||||||||||||
Debt periodic payment | $ 168,300 | ||||||||||||||||
Subsequent Event [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Interest rate | 10% | ||||||||||||||||
Payments of Debt Issuance Costs | $ 20,000 | ||||||||||||||||
Guaranteed Interest Contracts | 25,000 | ||||||||||||||||
Debt periodic payment | $ 39,285.71 | ||||||||||||||||
Reverse stock split | effected the 1-for-20 reverse stock split | ||||||||||||||||
Subsequent Event [Member] | Investor [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Stock Issued During Period, Shares, New Issues | 2,500 | ||||||||||||||||
Subsequent Event [Member] | Convertible Promissory Note [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Interest rate, stated percentage | 18% | 16% | 16% | ||||||||||||||
Subsequent Event [Member] | Licensing agreement [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
License agreement commitments description | On February 16, 2022, an addendum to the licensing agreement dated August 4, 2021, was executed by the Company and Melior Pharmaceuticals I, Inc, extending the requirement by the Company to raise $4.0 million dollars to June 16, 2022 | ||||||||||||||||
Subsequent Event [Member] | Securities purchase agreement [Member] | Convertible Redeemable Note [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Interest rate | 10% | ||||||||||||||||
Principal amount | $ 250,000 | ||||||||||||||||
Proceeds from Convertible Debt | 200,000 | ||||||||||||||||
Payments of Debt Issuance Costs | 50,000 | ||||||||||||||||
Subsequent Event [Member] | Securities purchase agreement [Member] | Convertible Redeemable Note [Member] | Institutional Investor [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Proceeds from Convertible Debt | $ 180,000 | ||||||||||||||||
Subsequent Event [Member] | Common Stock [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Debt interest amount, conversion of common stock, shares | 12,721 | ||||||||||||||||
Subsequent Event [Member] | Convertible Debt [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Interest rate | 16% | 16% | |||||||||||||||
Debt conversion, converted instrument, amount | $ 9,500 | ||||||||||||||||
Principal amount | $ 421 | ||||||||||||||||
Debt instrument, convertible, conversion price | $ 0.78 |